

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12Q 1/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/06776</b> <b>(43) International Publication Date:</b> 10 February 2000 (10.02.00)
<b>(21) International Application Number:</b> PCT/US99/16675 <b>(22) International Filing Date:</b> 22 July 1999 (22.07.99) <b>(30) Priority Data:</b> 60/094,391 28 July 1998 (28.07.98) US <b>(71) Applicant (for all designated States except US):</b> AXYS PHARMACEUTICALS, INC. [US/US]; 180 Kimball Way, South San Francisco, CA 94080 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GALVIN, Margaret [US/US]; 7768 Corte Promenade, Carlsbad, CA 92009 (US). MILLER, Andrew [US/US]; 2131 Old Stone Mill Drive, Cranbury, NJ 08512 (US). PENNY, Laura [US/US]; 3903 Falcon Street, San Diego, CA 92103 (US). RIEDY, Michael [US/US]; 4066 Gresham Street #B, San Diego, CA 92109 (US). <b>(74) Agent:</b> SHERWOOD, Pamela, J.; Bozicevic, Field & Francis LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> GENOTYPING HUMAN UDP-GLUCURONOSYLTRANSFERASE 2B4 (UGT2B4), 2B7 (UGT2B7) AND 2B15 (UGT2B15) GENES  <b>(57) Abstract</b>  Genetic polymorphisms are identified in the human UGT2B4, UGT2B7 and UGT2B15 genes that alter UGT2B activity. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell and <i>in vitro</i> models for drug metabolism.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**GENOTYPING HUMAN UDP-GLUCURONOSYLTRANSFERASE 2B4 (UGT2B4), 2B7  
(UGT2B7) and 2B15 (UGT2B15) GENES**

INTRODUCTION

5       The metabolic processes commonly involved in the biotransformation of xenobiotics have been classified into functionalization reactions (phase I reactions), in which lipophilic compounds are modified via monooxygenation, dealkylation, reduction, aromatization, or hydrolysis. These modified molecules can then be substrates for the phase II reactions, often called conjugation reactions, as they conjugate a functional group with a polar,  
10   endogenous compound. Drug glucuronidation, a major phase II conjugation reaction in the mammalian detoxification system, is catalyzed by the UDP-glucuronosyltransferases (UGTs) (Batt AM, et al. (1994) Clin Chim Acta 226:171-190; Burchell et al. (1995) Life Sci. 57:1819-31).

      The UGTs are a family of enzymes that catalyze the glucuronic acid conjugation of  
15   a wide range of endogenous and exogenous substrates including phenols, alcohols, amines and fatty acids. The reactions catalyzed by UGTs permit the conversion of a large range of toxic endogenous/xenobiotic compounds to more water-soluble forms for subsequent excretion (Parkinson A (1996) Toxicol Pathol 24:48-57).

      The UGT isoenzymes are located primarily in hepatic endoplasmic reticulum and  
20   nuclear envelope (Parkinson A (1996) Toxicol Pathol 24:48-57), though they are also expressed in other tissues such as kidney and skin. UGTs are encoded by a large multigene superfamily that has evolved to produce catalysts with differing but overlapping substrate specificities. Three families, UGT1, UGT2, and UGT8, have been identified within the superfamily. UGTs are assigned to one the subfamilies based on amino acid sequence  
25   identity, e.g., UGT1 family members have greater than 45% amino acid sequence identity (Mackenzie et al. (1997) Pharmacogenetics 7:255-69).

      A single gene encodes several human UGT1 isoforms, the substrate specificity of each of which is thought to arise from differential splicing of a number of substrate-specific 5-prime regions of a single mRNA transcript to a shared 3-prime portion. On the other hand,  
30   members of the mammalian UGT2 gene subfamily, which encode the odorant and steroid-metabolizing isoforms, show nucleotide differences in sequence throughout the length of the cDNAs. This suggested that the UGT2 isoenzymes are encoded by several independent genes. The UGT2 genes have been further divided on the basis of their tissue-specific expression patterns into the UGT2A gene subfamily, which encodes

olfactory-specific isoforms, and the UGT2B gene subfamily, which encodes steroid-metabolizing isoforms in the liver. Monaghan *et al.* (1994) Genomics 23:496-499 mapped the UGT2B9 and the UGT2B15 genes to chromosome 4q13, giving a provisional ordering of the genes as UGT2B9-UGT2B4-UGT2B15. The UGT2B subfamily contains  
5 phenobarbital-inducible genes, as well as numerous genes that are constitutively expressed and are involved in the glucuronidation of endogenous steroids and biogenic amines (Mackenzie, *et al. supra.*) Evidence suggests that UGT2B4 is exclusively expressed in human liver, and not in human kidney. Levesque *et al.* (1997) Pharmacogenetics 7:317; and Coffman *et al.* (1997) Drug Metabol. and Dispos. 25:1-4, describe UGT2B gene  
10 polymorphisms.

Alteration of the expression or function of UGTs may affect drug metabolism. For example, there may be common polymorphisms in the human UGT2B gene that alter expression or function of the protein product and cause drug exposure-related phenotypes. Thus, there is a need in the field to identify UGT2B polymorphisms in order to provide a  
15 better understanding of drug metabolism and the diagnosis of drug exposure-related phenotypes.

#### SUMMARY OF THE INVENTION

Genetic sequence polymorphisms are identified in the UGT2B4, UGT2B7 and  
20 UGT2B15 genes, herein generically referred to as "UGT2B genes". Nucleic acids comprising the polymorphic sequences are used in screening assays, and for genotyping individuals. The genotyping information is used to predict an individuals' rate of metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects. Specific polynucleotides include the polymorphic UGT2B4 sequences set forth in SEQ ID NOs:25-38;  
25 the polymorphic UGT2B7 sequences set forth in SEQ ID NOs:84-111; and the polymorphic UGT2B15 sequences set forth in SEQ ID NOs:147-164.

The nucleic acid sequences of the invention may be provided as probes for detection of UGT2B locus polymorphisms, where the probe comprises a polymorphic sequence of SEQ ID NOs:25-38; 84-111 and 147-164. The sequences may further be utilized as an  
30 array of oligonucleotides comprising two or more probes for detection of UGT2B locus polymorphisms.

Another aspect of the invention provides a method for detecting in an individual a polymorphism in UGT2B metabolism of a substrate, where the method comprises analyzing the genome of the individual for the presence of at least one UGT2B polymorphism; wherein

the presence of the predisposing polymorphism is indicative of an alteration in UGT2B expression or activity. The analyzing step of the method may be accomplished by detection of specific binding between the individual's genomic DNA with an array of oligonucleotides comprising UGT2B locus polymorphic sequences. In other embodiments, the alteration in

5 UGT2B expression or activity is tissue specific, or is in response to a UGT2B modifier that induces or inhibits UGT2B expression.

#### BRIEF DESCRIPTION OF THE SEQUENCE LISTING

*UGT2B Reference Sequences.* SEQ ID NOs: 1-6 list the sequence of the reference

10 UGT2B4 exons, where exon 1 is SEQ ID NO:1, exon 2 is SEQ ID NO:2 and so forth. Partial sequence of the flanking introns is included; the boundaries are annotated in the SEQLIST. The cDNA sequence is set forth in SEQ ID NO:7, and the encoded amino acid sequence in SEQ ID NO:8.

SEQ ID NO:39 lists the sequence of the UGT2B7 cDNA sequence, the encoded

15 polypeptide is provided in SEQ ID NO:40. SEQ ID NOs: 41-45 list the sequence of the reference UGT2B7 exons, where exon 1 is SEQ ID NO:41, exon 2 is SEQ ID NO:42 and so forth. Partial sequence of the flanking introns is included; the boundaries are annotated in the SEQLIST.

SEQ ID NO:112 lists the sequence of the UGT2B15 cDNA sequence, the encoded

20 polypeptide is provided in SEQ ID NO:113. SEQ ID NOs:114-118 list the sequence of the reference UGT2B15 exons, where exon 1 is SEQ ID NO:114, exon 2 is SEQ ID NO:115 and so forth. Partial sequence of the flanking introns is included; the boundaries are annotated in the SEQLIST.

*Primers.* The PCR primers for amplification of polymorphic sequences are set forth

25 as SEQ ID NOs:9-14; 46-66; and 135-146. The primers used in sequencing isolated polymorphic sequences are presented as SEQ ID NOs:15-24; 67-83; and 119-134.

*Polymorphisms.* Polymorphic sequences of UGT2B4 are presented as SEQ ID NOs:25-38. Polymorphic sequences of UGT2B7 are presented as SEQ ID NOs:84-111. Polymorphic sequences of UGT2B15 are presented as SEQ ID NO:147-164.

30

## DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Pharmacogenetics is the association between an individual's genotype and that individual's ability to metabolize or react to a therapeutic agent. Differences in metabolism or target sensitivity can lead to severe toxicity or therapeutic failure by altering the relation  
5 between bioactive dose and blood concentration of the drug. Relationships between polymorphisms in metabolic enzymes or drug targets and both response and toxicity can be used to optimize therapeutic dose administration.

Genetic polymorphisms are identified in the UGT2B4, UGT2B7 and UGT2B15 genes. Nucleic acids comprising the polymorphic sequences are used to screen patients for altered  
10 metabolism for UGT2B substrates, potential drug-drug interactions, and adverse/side effects, as well as diseases that result from environmental or occupational exposure to toxins. The nucleic acids are used to establish animal, cell culture and *in vitro* cell-free models for drug metabolism.

15 Definitions

It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, constructs, and reagents described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present  
20 invention which will be limited only by the appended claims.

As used herein the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a construct" includes a plurality of such constructs and reference to "the UGT2B nucleic acid" includes reference to one or more nucleic acids and equivalents thereof known to those skilled in the art, and  
25 so forth. All technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs unless clearly indicated otherwise.

*UGT2B4 reference sequence.* The sequence of human UGT2B4 cDNA may be  
30 accessed through Genbank, accession number Y00317, and is provided in SEQ ID NOs:1-7.

The amino acid sequence of UGT2B4 is listed as SEQ ID NO:8. The sequence of human UGT2B7 may be accessed through Genbank, accession number 600068, and in the SEQLIST as described above. The sequence of human UGT2B15 may be accessed through Genbak, accession number 600069, and in the SEQLIST as described above. The

nucleotide sequences provided herein differ from the published sequence at certain positions throughout the sequence. Where there is a discrepancy the provided sequence is used as a reference.

5 The term "wild-type" may be used to refer to the reference coding sequences of UGT2B4, UGT2B7 and UGT2B15, and the term "variant", or "UGT2B" to refer to the provided variations in the UGT2B sequences. The UGT2B4, UGT2B7 and UGT2B15 sequences are generically referred to as "UGT2B", and may be further distinguished by the species, *e.g.* human, mouse, *etc.*, or by the specific gene number, *e.g.* UGT2B4, UGT2B7, *etc.* Where there is no published form, such as in the intron sequences, the term wild-type  
10 may be used to refer to the most commonly found allele. It will be understood by one of skill in the art that the designation as "wild-type" is merely a convenient label for a common allele, and should not be construed as conferring any particular property on that form of the sequence.

15 *UGT2B polymorphic sequences.* It has been found that specific sites in the UGT2B4, UGT2B7 and UGT2B15 genes sequence are polymorphic, *i.e.* within a population, more than one nucleotide (G, A, T, C) is found at a specific position. Polymorphisms may provide functional differences in the genetic sequence, through changes in the encoded polypeptide, changes in mRNA stability, binding of transcriptional and translation factors to  
20 the DNA or RNA, and the like. The polymorphisms are also used as single nucleotide polymorphisms (SNPs) to detect genetic linkage to phenotypic variation in activity and expression of the particular UGT2B protein.

SNPs are generally biallelic systems, that is, there are two alleles that an individual may have for any particular marker. SNPs, found approximately every kilobase, offer the  
25 potential for generating very high density genetic maps, which will be extremely useful for developing haplotyping systems for genes or regions of interest, and because of the nature of SNPs, they may in fact be the polymorphisms associated with the disease phenotypes under study. The low mutation rate of SNPs also makes them excellent markers for studying complex genetic traits.

30 SNPs are provided in the UGT2B4, UGT2B7 and UGT2B15 intron and exon sequences. Tables 4, 7 and 10, and the corresponding sequence listing, provide both forms of each polymorphic sequence. For example, SEQ ID NO:37 and 38 are the alternative forms of a single polymorphic site. The provided sequences also encompass the complementary sequence corresponding to any of the provided polymorphisms.

In order to provide an unambiguous identification of the specific site of a polymorphism, sequences flanking the polymorphic site are shown in the tables, where the 5' and 3' flanking sequence is non-polymorphic, and the central position, shown in bold, is variable. It will be understood that there is no special significance to the length of non-polymorphic flanking sequence that is included, except to aid in positioning the polymorphism in the genomic sequence. The UGT2B exon sequences have been published, and therefore one of each pair of the sequences from exons in Tables 4, 7 and 10 are publically known sequence. The intron sequence has not been published, and hence both forms of this polymorphic sequence is novel.

As used herein, the term "UGT2B4, UGT2B7 and UGT2B15 genes" is intended to generically refer to both the wild-type and variant forms of the sequence, unless specifically denoted otherwise. As it is commonly used in the art, the term "gene" is intended to refer to the genomic region encompassing the 5' UTR, exons, introns, and the 3' UTR. Individual segments may be specifically referred to, *e.g.* exon 2, intron 5, *etc.* Combinations of such segments that provide for a complete UGT2B protein may be referred to generically as a protein coding sequence.

Nucleic acids of interest comprise the provided UGT2B<sup>v</sup> nucleic acid sequence(s), as set forth in Tables 4, 7 and 10. Such nucleic acids include short hybridization probes, protein coding sequences, variant forms of UGT2B cDNA, segments, *e.g.* exons, introns, *etc.*, and the like. Methods of producing nucleic acids are well-known in the art, including chemical synthesis, cDNA or genomic cloning, PCR amplification, *etc.*

For the most part, DNA fragments will be of at least 15 nt, usually at least 20 nt, often at least 50 nt. Such small DNA fragments are useful as primers for PCR, hybridization screening, *etc.* Larger DNA fragments, *i.e.* greater than 100 nt are useful for production of the encoded polypeptide, promoter motifs, *etc.* For use in amplification reactions, such as PCR, a pair of primers will be used. The exact composition of primer sequences is not critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art.

The UGT2B nucleic acid sequences are isolated and obtained in substantial purity, generally as other than an intact or naturally occurring mammalian chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include a UGT2B sequence or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", *i.e.* flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.



For screening purposes, hybridization probes of the polymorphic sequences may be used where both forms are present, either in separate reactions, spatially separated on a solid phase matrix, or labeled such that they can be distinguished from each other. Assays may utilize nucleic acids that hybridize to one or more of the described polymorphisms.

5 An array may include all or a subset of the polymorphisms listed in Tables 4, 7 and 10. One or both polymorphic forms may be present in the array, for example the polymorphism of SEQ ID NO:37 and 38 may be represented by either, or both, of the listed sequences. Usually such an array will include at least 2 different polymorphic sequences, *i.e.* polymorphisms located at unique positions within the locus, and may include all of the  
10 provided polymorphisms. Arrays of interest may further comprise sequences, including polymorphisms, of other genetic sequences, particularly other sequences of interest for pharmacogenetic screening, *e.g.* UGT1, other UGT2 sequences, cytochrome oxidase polymorphisms, *etc.* The oligonucleotide sequence on the array will usually be at least about 12 nt in length, may be the length of the provided polymorphic sequences, or may extend  
15 into the flanking regions to generate fragments of 100 to 200 nt in length. For examples of arrays, see Ramsay (1998) Nat. Biotech. 16:40-44; Hacia *et al.* (1996) Nature Genetics 14:441-447; Lockhart *et al.* (1996) Nature Biotechnol. 14:1675-1680; and De Risi *et al.* (1996) Nature Genetics 14:457-460.

Nucleic acids may be naturally occurring, *e.g.* DNA or RNA, or may be synthetic  
20 analogs, as known in the art. Such analogs may be preferred for use as probes because of superior stability under assay conditions. Modifications in the native structure, including alterations in the backbone, sugars or heterocyclic bases, have been shown to increase intracellular stability and binding affinity. Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are  
25 substituted with sulfur; phosphoroamidites; alkyl phosphotriesters and boranophosphates. Achiral phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH<sub>2</sub>-5'-O-phosphonate and 3'-NH-5'-O-phosphoroamidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage.

Sugar modifications are also used to enhance stability and affinity. The  $\alpha$ -anomer  
30 of deoxyribose may be used, where the base is inverted with respect to the natural  $\beta$ -anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-O-allyl sugars, which provides resistance to degradation without compromising affinity.

Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and

5-bromo-2'-deoxycytidine for deoxycytidine. 5-propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

5 *UGT2B polypeptides.* A subset of the provided nucleic acid polymorphisms in UGT2B exons confer a change in the corresponding amino acid sequence. Using the amino acid sequence provided in SEQ ID NO:8 as a reference for UGT2B4, the amino acid polymorphisms of the invention include lys→asn, pos. 40; and glu→asp, pos. 454. Using the amino acid sequence provided in SEQ ID NO:40 as a reference for UGT2B7, the amino acid  
10 polymorphisms of the invention include leu→phe, pos. 107; thr→ile, pos. 179; and lys→gln, pos. 430. Using the amino acid sequence provided in SEQ ID NO:125 as a reference for UGT2B15, the amino acid polymorphisms of the invention include ser→gly, pos. 15; asp→tyr, pos. 85; leu→pro, pos. 170; his→gln, pos. 282; ala→val, pos. 398; val→ile, pos. 443; and thr→lys, pos. 523.

15 Polypeptides comprising at least one of the provided polymorphisms (UGT2B<sup>v</sup> polypeptides) are of interest. The term "UGT2B<sup>v</sup> polypeptides" as used herein includes complete UGT2B protein forms, e.g. such splicing variants as known in the art, and fragments thereof, which fragments may comprise short polypeptides, epitopes, functional domains; binding sites; *etc.*; and including fusions of the subject polypeptides to other  
20 proteins or parts thereof. Polypeptides will usually be at least about 8 amino acids in length, more usually at least about 12 amino acids in length, and may be 20 amino acids or longer, up to substantially the complete protein.

The UGT2B4, UGT2B7 and UGT2B15 genetic sequences, including polymorphisms, may be employed for polypeptide synthesis. For expression, an expression cassette may  
25 be employed, providing for a transcriptional and translational initiation region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region. Various transcriptional initiation regions may be employed that are functional in the expression host. The polypeptides may be expressed in prokaryotes or  
30 eukaryotes in accordance with conventional ways, depending upon the purpose for expression. Small peptides can also prepared by chemical synthesis.

**Substrate.** A substrate is a chemical entity that is modified by UGT2B4, UGT2B7 or UGT2B15, usually under normal physiological conditions. Although the duration of drug action tends to be shortened by metabolic transformation, drug metabolism is not "detoxification". Frequently the metabolic product has greater biologic activity than the drug itself. In some cases the desirable pharmacologic actions are entirely attributable to metabolites, the administered drugs themselves being inert. Likewise, the toxic side effects of some drugs may be due in whole or in part to metabolic products.

Substrates can be either endogenous substrates, *i.e.* substrates normally found within the natural environment of UGT2B, such as estriol, or exogenous, *i.e.* substrates that are not normally found within the natural environment of UGT2B. UGT2B catalyzes glucuronidation of its substrates. The enzymes are specific for UDP-glucuronic acid, and not other UDP sugars.

Exemplary UGT2B4 substrates (*i.e.*, substrates of wild-type UGT2B4 and/or UGT2B4<sup>v</sup> polypeptides) include, but are not necessarily limited to estriol and the catechol estrogens 4-hydroxyestrone, and 2-hydroxyestriol, 2-aminophenol, 4-methylumbelliferone, 1-naphthol, 4-hydroxybiphenyl and 4-nitrophenol, 2-aminophenol, 4-hydroxybiphenyl, menthol, *etc.*, among other substrates (Burchell *et al.* (1991) DNA Cell Biol 10:487-494, Jin CJ, *et al.* (1993) Biochem Biophys Res Commun 194:496-503).

Exemplary UGT2B7 substrates (*i.e.*, substrates of wild-type UGT2B7 and/or UGT2B7<sup>v</sup> polypeptides) include, but are not necessarily limited to oxazepam, hyodeoxycholic acid, estriol, S-naproxen, ketoprofen, ibuprofen, fenoprofen, clofibric acid (Patel *et al* (1995) Pharmacogenetics 5(1):43-49), morphine (Coffman *et al* (1997) Drug Metabolism and Disposition 25:1-4), DMXAA (5,6-dimethylxantheonone-4-acetic acid) (Miners *et al* (1997) Cancer Res 57:284), 2-Hydroxy AAF, 4 methylumbelliferone, carboxylic acid drugs (BP-7,8-trans diol) (Burchell *et al.*, *supra.*)

Exemplary UGT2B15 substrates (*i.e.*, substrates of wild-type UGT2B15 and/or UGT2B15<sup>v</sup> polypeptides) include, but are not necessarily limited to 4-hydroxybiphenyl, 1-naphthol, 4 methylumbelliferone, naringenin, eugenol (Burchell *et al.*, *supra.*), simple phenolic compounds, 7-hydroxylated coumarins, flavonoids, anthraquinones; endogenous estrogens and androgens (Green *et al.* (1994) Drug Metabolism and Disposition 22:799).

**Modifier.** A modifier is a chemical agent that modulates the action of a UGT2B molecule, either through altering its enzymatic activity (enzymatic modifier) or through

modulation of expression (expression modifier, e.g., by affecting transcription or translation). In some cases the modifier may also be a substrate.

*Pharmacokinetic parameters.* Pharmacokinetic parameters provide fundamental data for designing safe and effective dosage regimens. A drug's volume of distribution, clearance, and the derived parameter, half-life, are particularly important, as they determine the degree of fluctuation between a maximum and minimum plasma concentration during a dosage interval, the magnitude of steady state concentration and the time to reach steady state plasma concentration upon chronic dosing. Parameters derived from *in vivo* drug administration are useful in determining the clinical effect of a particular UGT2B genotype.

*Expression assay.* An assay to determine the effect of a sequence polymorphism on UGT2B expression. Expression assays may be performed in cell-free extracts, or by transforming cells with a suitable vector. Alterations in expression may occur in the basal level that is expressed in one or more cell types, or in the effect that an expression modifier has on the ability of the gene to be inhibited or induced. Expression levels of a variant alleles are compared by various methods known in the art. Methods for determining promoter or enhancer strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as  $\beta$ -galactosidase, luciferase, chloramphenicol acetyltransferase, etc. that provides for convenient quantitation; and the like.

Gel shift or electrophoretic mobility shift assay provides a simple and rapid method for detecting DNA-binding proteins (Ausubel, F.M. *et al.* (1989) In: Current Protocols in Molecular Biology, Vol. 2, John Wiley and Sons, New York). This method has been used widely in the study of sequence-specific DNA-binding proteins, such as transcription factors. The assay is based on the observation that complexes of protein and DNA migrate through a nondenaturing polyacrylamide gel more slowly than free DNA fragments or double-stranded oligonucleotides. The gel shift assay is performed by incubating a purified protein, or a complex mixture of proteins (such as nuclear or cell extract preparations), with an end-labeled DNA fragment containing the putative protein binding site. The reaction products are then analyzed on a nondenaturing polyacrylamide gel. The specificity of the DNA-binding protein for the putative binding site is established by competition experiments using DNA fragments or oligonucleotides containing a binding site for the protein of interest, or other unrelated DNA sequences.

Expression assays can be used to detect differences in expression of polymorphisms with respect to tissue specificity, expression level, or expression in response to exposure to various substrates, and/or timing of expression during development. For example, since UGT2B4 is expressed in liver, polymorphisms could be evaluated for expression in tissues  
5 other than liver, or expression in liver tissue relative to a reference UGT2B4 polypeptide.

*Substrate screening assay.* Substrate screening assays are used to determine the metabolic activity of a UGT2B protein or peptide fragment on a substrate. Many suitable assays are known in the art, including the use of primary or cultured cells, genetically  
10 modified cells (e.g., where DNA encoding the UGT2B polymorphism to be studied is introduced into the cell within an artificial construct), cell-free systems, e.g. microsomal preparations or recombinantly produced enzymes in a suitable buffer, or in animals, including human clinical trials (see, e.g., Burchell et al. (1995) Life Sci. 57:1819-1831, specifically incorporated herein by reference. Where genetically modified cells are used, since most cell  
15 lines do not express UGT2B activity (liver cells lines being the exception), introduction of artificial construct for expression of the UGT2B polymorphism into many human and non-human cell lines does not require additional modification of the host to inactivate endogenous UGT2B expression/activity. Clinical trials may monitor serum, urine, etc. levels of the substrate or its metabolite(s).

20 Typically a candidate substrate is input into the assay system, and the conversion to a metabolite is measured over time. The choice of detection system is determined by the substrate and the specific assay parameters. Assays are conventionally run, and will include negative and positive controls, varying concentrations of substrate and enzyme, etc.

25 *Genotyping:* UGT2B genotyping is performed by DNA or RNA sequence and/or hybridization analysis of any convenient sample from a patient, e.g. biopsy material, blood sample (serum, plasma, etc.), buccal cell sample, etc. A nucleic acid sample from an individual is analyzed for the presence of polymorphisms in UGT2B, particularly those that affect the activity or expression of UGT2B. Specific sequences of interest include any  
30 polymorphism that leads to changes in basal expression in one or more tissues, to changes in the modulation of UGT2B expression by modifiers, or alterations in UGT2B substrate specificity and/or activity.

*Linkage Analysis:* Diagnostic screening may be performed for polymorphisms that are genetically linked to a phenotypic variant in UGT2B activity or expression, particularly through the use of microsatellite markers or SNPs. The microsatellite marker or SNP itself may not phenotypically expressed, but is linked to sequences that result in altered activity or expression. Two polymorphic variants may be in linkage disequilibrium, *i.e.* where alleles show non-random associations between genes even though individual loci are in Hardy-Weinberg equilibrium.

Linkage analysis may be performed alone, or in combination with direct detection of phenotypically evident polymorphisms. The use of microsatellite markers for genotyping is well documented. For examples, see Mansfield *et al.* (1994) Genomics 24:225-233; and Ziegler *et al.* (1992) Genomics 14:1026-1031. The use of SNPs for genotyping is illustrated in Underhill *et al.* (1996) Proc Natl Acad Sci U S A 93:196-200.

*Transgenic animals.* The subject nucleic acids can be used to generate genetically modified non-human animals or site specific gene modifications in cell lines. The term "transgenic" is intended to encompass genetically modified animals having a deletion or other knock-out of UGT2B4, UGT2B7 or UGT2B15 activity, having an exogenous UGT2B4, UGT2B7 or UGT2B15 gene that is stably transmitted in the host cells, or having an exogenous UGT2B promoter operably linked to a reporter gene. Transgenic animals may be made through homologous recombination, where the UGT2B locus is altered. Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like. Of interest are transgenic mammals, *e.g.* cows, pigs, goats, horses, *etc.*, and particularly rodents, *e.g.* rats, mice, *etc.*

25

*Genetically Modified Cells.* Primary or cloned cells and cell lines are modified by the introduction of vectors comprising UGT2B4, UGT2B7 and UGT2B15 genetic polymorphisms. The gene may comprise one or more variant sequences, preferably a haplotype of commonly occurring combinations. In one embodiment of the invention, a panel of two or more genetically modified cell lines, each cell line comprising a UGT2B polymorphism, are provided for substrate and/or expression assays. The panel may further comprise cells genetically modified with other genetic sequences, including polymorphisms, particularly other sequences of interest for pharmacogenetic screening, *e.g.* UGT1, other UGT2 sequences, cytochrome oxidase polymorphisms, *etc.*

30

Vectors useful for introduction of the gene include plasmids and viral vectors, e.g. retroviral-based vectors, adenovirus vectors, etc. that are maintained transiently or stably in mammalian cells. A wide variety of vectors can be employed for transfection and/or integration of the gene into the genome of the cells. Alternatively, micro-injection may be employed, fusion, or the like for introduction of genes into a suitable host cell.

#### Genotyping Methods

The effect of a polymorphism in the UGT2B4, UGT2B7 or UGT2B15 gene sequence on the response to a particular substrate or modifier is determined by *in vitro* or *in vivo* assays. Such assays may include monitoring the metabolism of a substrate during clinical trials to determine the UGT2B enzymatic activity, specificity or expression level. Generally, *in vitro* assays are useful in determining the direct effect of a particular polymorphism, while clinical studies will also detect an enzyme phenotype that is genetically linked to a polymorphism.

The response of an individual to the substrate or modifier can then be predicted by determining the UGT2B genotype, with respect to the polymorphism. Where there is a differential distribution of a polymorphism by racial background, guidelines for drug administration can be generally tailored to a particular ethnic group.

The basal expression level in different tissue may be determined by analysis of tissue samples from individuals typed for the presence or absence of a specific polymorphism. Any convenient method may be used, e.g. ELISA, RIA, etc. for protein quantitation, northern blot or other hybridization analysis, quantitative RT-PCR, etc. for mRNA quantitation. The tissue specific expression is correlated with the genotype.

The alteration of UGT2B expression in response to a modifier is determined by administering or combining the candidate modifier with an expression system, e.g. animal, cell, *in vitro* transcription assay, etc. The effect of the modifier on UGT2B transcription and/or steady state mRNA levels is determined. As with the basal expression levels, tissue specific interactions are of interest. Correlations are made between the ability of an expression modifier to affect UGT2B activity, and the presence of the provided polymorphisms. A panel of different modifiers, cell types, etc. may be screened in order to determine the effect under a number of different conditions.

A UGT2B polymorphism that results in altered enzyme activity or specificity is determined by a variety of assays known in the art. The enzyme may be tested for metabolism of a substrate *in vitro*, for example in defined buffer, or in cell or subcellular

lysates, where the ability of a substrate to be metabolized by UGT2B4, UGT2B7 or UGT2B15 under physiologic conditions is determined. Where there are not significant issues of toxicity from the substrate or metabolite(s), *in vivo* human trials may be utilized, as previously described.

5       The genotype of an individual is determined with respect to the provided UGT2B4, UGT2B7 and UGT2B15 polymorphisms. The genotype is useful for determining the presence of a phenotypically evident polymorphism, and for determining the linkage of a polymorphism to phenotypic change.

10       A number of methods are available for analyzing nucleic acids for the presence of a specific sequence. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. The nucleic acid may be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis. The use of the polymerase chain reaction is described in Saiki *et al.* (1985)  
15       Science **230**:1350-1354, and a review of current techniques may be found in Sambrook *et al.* Molecular Cloning: A Laboratory Manual, CSH Press 1989, pp.14.2-14.33. Amplification may be used to determine whether a polymorphism is present, by using a primer that is specific for the polymorphism. Alternatively, various methods are known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, for examples see Riley *et al.* (1990) Nucleic Acids Res **18**:2887-2890; and Delahunty *et al.* (1996) Am J Hum Genet  
20       **58**:1239-1246.

25       A detectable label may be included in an amplification reaction. Suitable labels include fluorochromes, e.g. fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, e.g. <sup>32</sup>P, <sup>35</sup>S, <sup>3</sup>H; etc. The label may be a two stage system, where the amplified DNA is conjugated to biotin, haptens, etc. having a high affinity binding partner, e.g. avidin, specific antibodies, etc., where the binding partner  
30       is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

      The sample nucleic acid, e.g. amplified or cloned fragment, is analyzed by one of a number of methods known in the art. The nucleic acid may be sequenced by dideoxy or



other methods. Hybridization with the variant sequence may also be used to determine its presence, by Southern blots, dot blots, *etc.* The hybridization pattern of a control and variant sequence to an array of oligonucleotide probes immobilized on a solid support, as described in U.S. 5,445,934, or in WO95/35505, may also be used as a means of detecting the presence of variant sequences. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), mismatch cleavage detection, and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease (restriction fragment length polymorphism, RFLP), the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

In one embodiment of the invention, an array of oligonucleotides are provided, where discrete positions on the array are complementary to one or more of the provided polymorphic sequences, e.g. oligonucleotides of at least 12 nt, frequently 20 nt, or larger, and including the sequence flanking the polymorphic position. Such an array may comprise a series of oligonucleotides, each of which can specifically hybridize to a different polymorphism. For examples of arrays, see Hacia *et al.* (1996) Nat Genet 14:441-447 and DeRisi *et al.* (1996) Nat Genet 14:457-460.

The genotype information is used to predict the response of the individual to a particular UGT2B substrate or modifier. Where an expression modifier inhibits UGT2B expression, then drugs that are a UGT2B substrate will be metabolized more slowly if the modifier is co-administered. Where an expression modifier induces UGT2B expression, a co-administered substrate will typically be metabolized more rapidly. Similarly, changes in UGT2B activity will affect the metabolism of an administered drug. The pharmacokinetic effect of the interaction will depend on the metabolite that is produced, e.g. a prodrug is metabolized to an active form, a drug is metabolized to an inactive form, an environmental compound is metabolized to a toxin, *etc.* Consideration is given to the route of administration, drug-drug interactions, drug dosage, *etc.*

#### EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention,

and are not intended to limit the scope of what is regarded as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (e.g., amounts, temperature, concentrations, etc.) but some experimental errors and deviations should be allowed for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees centigrade; and pressure is at or near atmospheric.

## EXAMPLE 1

## Genotyping UGT2B4

10 Materials and Methods

*DNA Samples.* Blood specimens from approximately 48 individuals were collected after obtaining informed consent. All samples were stripped of personal identifiers to maintain confidentiality. The only data associated with a given blood samples was gender and self-reported major racial group designations in the United States (Caucasian, Hispanic, African American). Genomic DNA was isolated from these samples using standard techniques. DNA was stored either as a concentrated solution, or in a dried form in microtiter plates.

*PCR amplifications.* The primers used to amplify exons in which polymorphisms were found are shown in Table 1, and were designed with NBI's Oligo version 5.1 program. Sequences for exons in which no polymorphisms were found are not shown.

Table 1. UGT2B4 PCR Primers.

Region	Primary PCR Amplification		
	Forward/ Reverse	SEQ ID NO	Sequence
UGT2B4Exon 1	F	9.	Taccttttagtgtctcttgtca
	R	10.	Ttctggagtcttctgtatga
UGT2B4Exon 4	F	11.	Catcccttggtctctcatt
	R	12.	Cgggactggaaaataaatat
UGT2B4Exon 6	F	13.	Ggggttcaccgtgtta
	R	14.	Aagccaagcagcactaa

Twenty-five nanograms of gDNA were amplified in the primary amplifications using the Perkin Elmer GeneAmp PCR kit according to the manufacturer's instructions in 25  $\mu$ l reactions with AmpliTaq Gold DNA polymerase. Reactions contained 25 mM  $MgCl_2$  and 0.2  $\mu$ M of each primer. Thermal cycling was performed using a GeneAmp PCR System 9600

PCR machine (Perkin Elmer), utilizing a touch-down PCR protocol. The protocol, unless indicated otherwise in Table 2, consisted of an initial incubation of 95°C for 10 min, followed by ten cycles of 95°C for 20 sec, 64°C (minus 1°C per cycle) for 20 sec, 72°C for 2 min, six cycles of 95°C for 20 sec, 54°C for 20 sec, 72°C for 2 min, and nineteen cycles of 95°C for 20 sec, 54°C for 20 sec, 72°C for 2 min (plus 15 sec per cycle), and one final extension step of 72°C for 10 min.

For the secondary PCR reactions, one microliter of each primary PCR reaction was re-amplified using the primary PCR primers. The thermal cycling profile that was used for the primary PCR for an exon was also used for the secondary PCR.

10

Table 2.  
Cycling Profile Modifications

Exon	Primary PCR	Secondary PCR
1	Touch-Down PCR step: 8 cycles	same as Primary PCR
	64° C (minus 1° C per cycle), for 15 sec	
	Total Number of cycles: 35	
4	Touch-Down PCR step: 10 cycles	same as Primary PCR
	64° C (minus 1° C per cycle), for 15 sec	
	Total Number of cycles: 35	
6	Touch-Down PCR step: 7 cycles	same as Primary PCR
	64° C (minus 1° C per cycle), for 15 sec	
	Total Number of cycles: 35	

*DNA sequencing.* PCR products from 48 individuals (approximately 1/3 African American, 1/3 Caucasian, 1/3 Hispanic) were prepared for sequencing by treating 8 µl of each PCR product with 0.15 µl of exonuclease I (1.5 U/reaction), 0.3 µl of Shrimp Alkaline Phosphatase (0.3U/reaction), q.s. to 10 µl with MilliQ water, and incubated at 37°C for 30 min, followed by 72°C for 15 min. Cycle sequencing was performed on the GeneAmp PCR System 9600 PCR machine (Perkin Elmer) using the ABI Prism dRhodamine Terminator Cycle Sequencing Ready Reaction Kit according to the manufacturer's directions, with the following changes: (1) 2 µl of dRhodamine terminator premix, instead of 8 µl, (2) 10% (v/v) Dimethylsulfoxide was added to each individual nucleotide. The oligonucleotide primers (unlabelled), at 3 picomoles per reaction, used for the sequencing reactions are listed in

Table 3. Sequencing reactions, with a final volume of 5  $\mu$ l, were subjected to 25 cycles at 96°C for 10 sec, 50°C for 5 sec, and 60°C for 4 min, followed by ethanol precipitation. After decanting the ethanol, samples were evaporated to dryness using a SpeedVac for roughly 15 min and were resuspended in 2  $\mu$ l of loading buffer (5:1 deionized formamide:50 mM EDTA pH 8.0), heated to 94°C for 2 min, and were electrophoresed through 5.25% polyacrylamide/6M urea gels in an ABI Prism 377 DNA Sequencer, according to the manufacturer's instructions for sequence determination. All sequences were determined from both the 5' and 3' (sense and antisense) direction.

10

Table 3. Sequencing Primers

P. No.	F/R	SEQ ID NO	Forward Primer
1	F	15.	Ccacatgctcagactgtaa
	R	16.	Caaaaataccccactaccc
2	F	17.	Ccctgttcttctcattgta
	R	18.	Ttcagtaagcttggttcgat
3,4	F	19.	Cctggccaaattgactt
	R	20.	Caggaaccagtcacatc
5	F	21.	Ggggaaaagagattaattacg
	R	22.	Agccaagcagcactaatc
6,7	F	23.	Tccaattcacagggtacatg
	R	24.	Agccaagcagcactaatc

Table 4.  
Summary of UGT2B4 polymorphisms.

Exon	Nt change	AA change	SEQ ID	Sequence
1	G 157 C	Lys 40 Asn	25.	Tggatgaatataaagacaatcctggat
			26.	Tggatgaatataaacacaatcctggat
Int.4	T 61 C		27.	Aagtgttaatagttatcatgaaacaag
			28.	Aagtgttaatagctatcatgaaacaag
6	T 1411 A	Glu 454 Asp	29.	Tgaagccccttgatcgagcagcttct
			30.	Tgaagccccttgaacgagcagcttct
6	C 1412 A		31.	Tgaagccccttgatcgagcagcttct
			32.	Tgaagccccttgatagagcagcttct
6	T 1849 C		33.	Gatataaagccatacgagggttatattg
			34.	Gatataaagccatagagggttatattg
6	A 1919 C		35.	Caggttacatgaaaaaaaaatttacta
			36.	Caggttacatgaaaaacaatttacta
6	A 2072 G		37.	Ttgtgagggaagctaataaataattaa
			38.	Ttgtgagggaactaataaataattaa

5 Nucleotide variants in exons are numbered from first base in Sequence 1. Amino Acid changes are numbered beginning with the first methionine in the protein sequence provided in Sequence 1. The nucleotide variant in intron 4 is numbered from the beginning of intron 4, as provided in Sequence 2.4.

#### EXAMPLE 2

##### UGT2B7 Genotyping

10 Twenty-five nanograms of gDNA were amplified in the primary amplifications using the Perkin Elmer GeneAmp PCR kit according to the manufacturer's instructions in 25  $\mu$ l reactions with AmpliTaq Gold DNA polymerase. Reactions contained 25 mM  $MgCl_2$  and 0.2  $\mu$ M of each primer. Thermal cycling was performed using a GeneAmp PCR System 9600  
 15 PCR machine (Perkin Elmer), utilizing a touch-down PCR protocol. The exons for UGT2B7 were amplified using the following cycling conditions: An initial incubation at 96°C for 10 min., followed by 16 cycles of 95°C for 20 sec., 52°C for 20 sec., 72°C for 2 min., and nineteen cycles of 95°C for 20 sec, 52°C for 20 sec, 72°C for 2 min (plus 15 sec per cycle), and one final extension step of 72°C for 10 min.

For the secondary PCR reactions, one microliter of each primary PCR reaction was re-amplified using the primary PCR primers. The thermal cycling profile that was used for the primary PCR for an exon was also used for the secondary PCR.

The amplification primers are provided in Table 5, the sequencing primers in Table 6, and the polymorphisms in Table 7.

Table 5  
PCR Primers for UGT2B7 Amplification

Region		SEQ ID NO	Primer Sequence
UGT2B7 Exon 1	Primary F	46.	Cttggctaatttatctttgg
	Primary R	47.	Cccactaccctgactttat
	Secondary F	48.	Ggacataaccatgagaaatg
	Secondary R	49.	Agctctgctcaaagacac
UGT2B7 Exon 2	Primary F	50.	Tgtccgatgctactattgaa
	Primary R	51.	Tgtgctaacccttgtaa
	Secondary F	52.	Tttttttctattcctgtcag
	Secondary R	53.	Cttacccacccattt
UGT2B7 Exon 4	Primary F	54.	Ccctgatctcattcctact
	Primary R	55.	Aactggctattccttagatgtatg
	Secondary F	56.	Cattcctactcttatacagttctc
	Secondary R	57.	Cccccgattcagactat
UGT2B7 Exon 5	Primary F	58.	Ccctgatctcattcctact
	Primary R	59.	Aactggctattccttagatgtatg
	Secondary F	60.	Tcctccgaagtctgaaac
	Secondary R	61.	Tataaaaaggatgaaactcacac
UGT2B7 Exon 6	Primary F	62.	Caagccccaagttatgt
	Primary R	63.	Cagtaggatccgcatataa
	Secondary F	64.	Tctgaggggtttgtctgta
	Secondary R	65.	Ccgcatataagttcaacaa

10 *DNA sequencing.* PCR products from 48 individuals were prepared for sequencing by treating 8  $\mu$ L of each PCR product with 0.15  $\mu$ L of exonuclease I (1.5U/reaction), 0.3  $\mu$ L of Shrimp Alkaline Phosphatase (0.3U/reaction), q.s. to 10  $\mu$ L with MilliQ water, and incubated at 37°C for 30 min, followed by 72°C for 15 min. Cycle sequencing was performed

on the GeneAmp PCR System 9600 PCR machine (Perkin Elmer) using the ABI Prism dRhodamine Terminator Cycle Sequencing Ready Reaction Kit or the ABI Prism Big Dye Terminator Cycle Sequencing Ready Reaction Kit according to the manufacturer's directions, with the following changes: For the ABI Prism dRhodamine Terminator kit, (1) 2  $\mu$ L of  
5 dRhodamine terminator premix, instead of 8  $\mu$ L, (2) 10% (v/v) Dimethylsulfoxide was added to each individual nucleotide, (3) 5  $\mu$ L total volume instead of 20  $\mu$ L. For the ABI Prism Big Dye Terminator kit (1) 0.8  $\mu$ L of Big Dye terminator premix, instead of 8  $\mu$ L, and (2) 15  $\mu$ L total volume instead of 20  $\mu$ L. The oligonucleotide primers (unlabeled), at 3 picomoles per reaction, used for the sequencing reactions are listed in Table 6. Sequencing reactions, with  
10 a final volume of 5  $\mu$ L, were subjected to 25 cycles at 96°C for 10 sec, 50°C for 5 sec, and 60°C for 4 min, followed by ethanol precipitation. After decanting the ethanol, samples were evaporated to dryness using a SpeedVac for roughly 15 min and were resuspended in 2  $\mu$ L of loading buffer (5:1 deionized formamide:50 mM EDTA pH 8.0), heated to 94°C for 2 min, and were electrophoresed through 5.25% polyacrylamide/6M urea gels in an ABI Prism 377  
15 DNA Sequencer, according to the manufacturer's instructions for sequence determination. All sequences were determined from both the 5' and 3' (sense and antisense) direction.

Table 6  
Sequencing Primers UGT2B7

P. No.	F/R	SEQ ID NO	Primer Sequence
1, 2	F	66.	Ggacataacctgagaaatg
	R	67.	Ttaagagcggatgagttgt
3, 4	F	68.	Tcatcatgcaacagattaag
	R	69.	Cactacagggaaaaatagca
5	F	70.	Accctttgtgtacagtctca
	R	71.	Agctctgtctcaaagacac
6, 7	F	72.	Ttgctacattattctaacc
	R	73.	Ctttaccaccaccattt
8, 9	F	74.	Cattcctactctttatacagttctc
	R	75.	Cccccgattcagactat
10	F	76.	Cattcctactctttatacagttctc
	R	77.	Cccccgattcagactat
11, 12	F	78.	Tcctccgaagtctgaaac
	R	79.	Tataaaaaggatgaaactcacac
13	F	80.	Tctgaggggtttgtctgta
	R	81.	Tttttgtctcaggaagaaaga
14	F	82.	Aaaaaaagaaaaaaaaatcttttc
	R	83.	Ccgcatataagttcaacaa



Table 7  
Summary of Sequence Polymorphisms UGT2B7

N	Exon	Nt change	AA change	SEQ ID NO.	Sequence
1	1	G 13 A		84.	Tgcattgcaccaggatgtctgt
				85.	Tgcattgcaccaagatgtctgt
2	1	T 151 C	Leu 107 Phe	86.	Tcctggatgagcttattcagaga
				87.	Tcctggatgagcctattcagaga
3	1	A 236 T		88.	Cattttggttataattttcac
				89.	Cattttggtttattttcac
4	1	A 286 G		90.	Cataactagaaagtctgtaa
				91.	Cataactaggaagtctgtaa
5	1	C 450 T	Thr 179 Ile	92.	Cctggctacactttgaaaa
				93.	Cctggctacattttgaaaa
6	2	A 14 G		94.	Gaagaccactacattatctg
				95.	Gaagaccactacgttatctg
7	2	AT 80-81 TC		96.	Aattttcagtttccatccactctt
				97.	Aattttcagtttccatccactctt
8	4	C 57 G		98.	Taggtctcaatactcggctcta
				99.	Taggtctcaatactcggctgta
9	4	C 60 T		100.	Tacaagtgataacccaga
				101.	Tataagtgataacccaga
10	In.4	A 154 del		102.	Gggagaaagaatacattataattttt
				103.	Gggagaaagaataactataattttt
11	5	C 101 T		104.	Ttcattgtttgccgatcaac
				105.	Ttcattgtttgctgatcaac
12	5	A 198 C	Lys 430 Gln	106.	Gaatgcattgaagagagtaat
				107.	Gaatgcattgcagagagtaat
13	6	A 197 G		108.	Ctggctgtgtggcaactgtga
				109.	Ctggctgtgtggcgactgtga
14	6	C 528 A		110.	Taagataaagccttatgag
				111.	Taagataaagacttatgag

## Example 3

## Genotyping UGT2B15

Sequencing and analysis were performed as described in Example 2. The amplification primers are provided in Table 9, the sequencing primers in Table 8, and the polymorphisms in Table 10.

Table 8  
Sequencing Primers UGT2B15

Region		SEQ ID NO	Primer Sequence
UGT2B15 Exon 1	Primary F	119.	catgcacctaattcagactgt
	Primary R	120.	tgggtgtcctgtagtagtga
	Secondary F	121.	attgattttcctcagatataagta
	Secondary R	122.	tcataattcccttaaaaacac
UGT2B15 Exon 2	Primary F	123.	atatgttgggtatgtattcc
	Primary R	124.	ccatattcccctcactct
	Secondary F	125.	atacctgcatattcaataacaa
	Secondary R	126.	tatccagccattccttct
UGT2B15 Exon 5	Primary F	127.	agttttgtgggtataatgttac
	Primary R	128.	aaacgggttaaaattcata
	Secondary F	129.	tcataccttgtaattaataatttg
	Secondary R	130.	cgggttaaaattcatattca
UGT2B15 Exon 6	Primary F	131.	tcatgccaattcagtgac
	Primary R	132.	accctccatgctgaaat
	Secondary F	133.	tcaaagaccatccatagactt
	Secondary R	134.	ggagtcccattcttcagtc

Table 9  
PCR Primers UGT2B15

P. No.	F/R	SEQ ID NO	Primer Sequence
1,2	F	135.	Attgatttttcctcagatataagta
	R	136.	Attactggcattgacaag
3	F	137.	Attgatttttcctcagatataagta
	R	138.	Tgtacagaaagggtatgttaa
4	F	139.	aaaaat g/t atttgaagattc
	R	140.	Tcataatttccttaaaaacac
5	F	141.	Atacctgcatattcaaataacaa
	R	142.	Tatccagccattccttct
6,7	F	143.	Tcataccttgtaattaataatttg
	R	144.	Cgggttaaaattcatattca
8,9	F	145.	Tcaaagaccatccatagactt
	R	146.	Ggagtcccatcttcagtc

Table 10  
Summary of Sequence Polymorphisms UGT2B15

N	Exon	Ntd change	AA change	SEQ ID NO.	Sequence
1	1	A 53 G	Ser 15 Gly	147.	tgatacagctcagttgttac
				148.	tgatacagctcggttgttac
2	1	T 184 G		149.	tgttgacatcttcggcttct
				150.	tgttgacatcgtcggcttct
3	1	G 263 T	Asp 85 Tyr	151.	ctttaactaaaaatgatttgaa
				152.	ctttaactaaaaattatttgaa
4	1	T 519 C	Leu 170 Pro	153.	ttaacataccctttctgtaca
				154.	ttaacataccctttcgtaca
5	2	C 122 G	His 282 Gln	155.	tggaggacttcactgtaaacc
				156.	tggaggacttcagtgtaaacc
6	5	G 59 A		157.	tatgaggcgaatctaccatgggat
				158.	tatgaggcaatctaccatgggat
7	5	C 100 T	Ala 398 Val	159.	ccctgtttgcggatcaacatgat
				160.	ccctgtttgtggatcaacatgat
8	6	G 14 A	Val 443 Ile	161.	aaagagaatgcatgaaattat
				162.	aaagagaatcatgaaattat
9	6	C 523 A	Thr 523 Lys	163.	gcttgccaaaacaggaaagaa
				164.	gcttgccaaaaaggaaagaa

5 All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

10 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

What is Claimed is:

1. An isolated nucleic acid molecule comprising a UGT2B sequence polymorphism of SEQ ID NOs:25-38; 84-111 or 147-164, as part of other than a naturally occurring chromosome.
2. A nucleic acid probe for detection of UGT2B locus polymorphisms, comprising a polymorphic sequence of SEQ ID NOs:25-38; 84-111 or 147-164.
3. A nucleic acid probe according to Claim 2, wherein said probe is conjugated to a detectable marker.
4. An array of oligonucleotides comprising:  
two or more probes for detection of UGT2B locus polymorphisms, said probes comprising at least one form of a polymorphic sequences of SEQ ID NOs:25-38; 84-111 or 147-164.
5. A method for detecting in an individual a polymorphism in a UGT2B metabolism of a substrate, the method comprising:  
analyzing the genome of said individual for the presence of at least one UGT2B polymorphism of SEQ ID NOs:25-38; 84-111 or 147-164; wherein the presence of said predisposing polymorphism is indicative of an alteration in UGT2B expression or activity.
6. A method according to Claim 5, wherein said analyzing step comprises detection of specific binding between the genomic DNA of said individual with an array of oligonucleotides comprising:  
two or more probes for detection of UGT2B locus polymorphisms, said probes comprising at least one form of a polymorphic sequence of SEQ ID NOs:25-38; 84-111 or 147-164.
7. A method according to Claim 5, wherein said alteration in UGT2B expression is tissue specific.
8. A method according to Claim 5, wherein said alteration in UGT2B expression is in response to a UGT2B modifier.

9. A method according to Claim 8, wherein said modifier induces UGT2B expression.
- 5 10. A method according to Claim 8, wherein said modifier inhibits UGT2B expression.

## SEQUENCE LISTING

<110> Penny, Laura  
Galvin, Margaret  
Miller, Andrew  
Reidy, Michael

<120> Genotyping Human  
UDP-Glucuronosyltransferase 2B4 (UGT2B4), 2B7 (UGT2B7) and  
2B15 (UGT2B15) Genes

<130> SEQ-22PRV2

<160> 164

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1323

<212> DNA

<213> H. sapiens

<220>

<221> Other

<222> (140)... (897)

<400> 1

tcatctacct	tttagttgtc	tctttgtcat	ccacatgctc	agactgttaa	tataatgtat	60
ttactttgaa	gtgtaaaagt	tacattttta	cttcttgact	gatttatact	ggatgtcacc	120
atgagaaatg	acagaaagga	gcagcaactg	gaaaacaagc	attgcattgc	atcaggatgt	180
ctatgaaatg	gacttcagct	cttctgctga	tacagctgag	ctgttacttt	agctctggga	240
gttggtgaaa	ggtgctggtg	tggcccacag	aattcagcca	ctggatgaat	ataaagacaa	300
tcttgatga	acttgctcag	agaggtcatg	aggtgactgt	attggcatct	tcagcttcca	360
tttctttcga	tcccaacagc	ccatctactc	ttaaatttga	agtttatcct	gtatctttaa	420
ctaaaactga	gtttgaggat	attatcaagc	agctgggtta	gagatgggca	gaacttccaa	480
aagacacatt	ttggtcatat	tttccacaag	tacaagaaat	catgtggaca	tttaatgaca	540
tacttagaaa	gttctgtaag	gatatagttt	caaataagaa	acttatgaag	aaactacagg	600
agtcaagatt	tgatgttggt	cttgcatgag	ctgttttccc	ctttggtgag	ctgctggccg	660
agttacttaa	aatacccttt	gtctacagcc	tccgcttctc	tcctggctac	gcaattgaaa	720
agcatagtgg	aggacttctg	ttccctcctt	cctatgtgcc	tggtgttatg	tcagaactaa	780
gtgaccaaag	gactttcata	gagagggtta	aaaatatgat	ctatgtgctt	tattttgaat	840
tttggttcca	aatatttgac	atgaagaagt	gggatcagtt	ctacagtga	gttctaggta	900
agtaactttt	ttgattggtg	acatgaagat	ctaactttct	tgtacctttg	aagctgagtt	960
tgtataaagc	cataaagtca	gggtagtggg	gtatttttgt	aatgaattta	tcaaatgaaa	1020
ttgtaagatg	atctaccaa	ctcacaagca	ctatagaaaa	tgtaaattat	aggatcagtt	1080
aaaactctgt	ggccatcact	catacagaag	actccaggaa	gtcataagcc	tgtatattag	1140
tgcacctaa	atttctttta	gcaatcacat	atctgtttta	ttatacattt	tttcatctta	1200
aaaaaaagtc	agacttattc	agaaacatct	tgctgaatgc	atactggtag	attgagtagt	1260
tacacatttt	ttagaactat	ctatataaca	ttgcagaaat	tgttttttct	tgtatatttg	1320
cag						1323

<210> 2

<211> 746

<212> DNA

<213> H. sapiens

<220>

<221> Other  
<222> (195)...(344)

<400> 2

ttcttgtaaa	tacacatggg	taaaatatat	aatacataaa	aattaaatta	tgcctatata	60
cgaatatatg	tatttttttt	caaggcacia	acactttgcc	tacatttttg	cccacattat	120
tctaacttct	ttcagaaaat	tacctagttt	aattatcttg	tgatcatctat	cttttctttt	180
tttttcccc	atcaggaaga	cccactacgt	tatctgagac	aatggcaaaa	gctgacatat	240
ggcttattcg	aaactactgg	gattttcaat	ttcctcacc	actcttacca	aatgttgagt	300
tcgttggagg	actccactgc	aaacctgcca	aacctctacc	gaaggtaaac	tattactggt	360
tgttttgtct	gctttggaag	ttcagtagca	atggttctat	attcattcaa	agtgtttgac	420
ttacactgga	agaaaggtgg	aagtgggaag	agtaaaagcag	ataccaatta	gaaactgaag	480
tacatgttga	tactatcaca	agtttatgaa	tttcatcatt	attaccaata	aagagggata	540
ctaaagagac	tttgaaaata	gggttggtaa	attaaagctt	tgattatgca	acataataaga	600
aggtactggc	cattcattca	aagaatattt	ataaagagat	tagcacacac	cacaggtacg	660
tgatatggac	acagtttcta	tcccaacaca	ccttacattc	tattttgaaa	gatagaatat	720
atgcaagtaa	taaaaactgt	gtaaaa				746

<210> 3  
<211> 785  
<212> DNA  
<213> H. sapiens

<220>  
<221> Other  
<222> (238)...(369)

<400> 3

ttcacaaacg	cacacacata	cacacacaca	tatttacaca	aagaccctta	acagaggcaa	60
cctatctcat	attatacata	ttgcaaaaaa	aactgagtaa	ttgagtcagt	taaaaaacat	120
cctttactcc	aataattcct	gataaaactt	gattttctct	ctttttataa	caattctttc	180
acagtgcctg	ctgtgctgat	aatctattat	gatagaacaa	attctttttt	ttcacaggaa	240
atggaagagt	ttgtccagag	ctctggagaa	aatggtgttg	tggtgttttc	tctggggctg	300
atggtcagta	acacgtcaga	agaaagggcc	aatgttaattg	catcagccct	tgccaagatc	360
ccacaaaagg	taagataaaa	tgttttaatg	gtgtaaaaaa	ctactgaaag	aggctgttaa	420
agtttgtaaa	gaacccaatt	gtagaaactt	cctgcctata	tattcagctg	ttgggaaagc	480
actaattatc	tcagatatta	attcaaaatc	aaaaatatgt	atggaagatg	ataaactcat	540
acagaaggtg	tttttcattg	gtaattaatt	tggtcatat	attgtgatca	ggaataaata	600
caattaagag	ttgcaggtaa	agttttggtg	ttatcatgat	actggggctc	ggtaagagct	660
atcaccaaat	tctgcccctg	tgatttgatc	cttttggtta	agaactcctg	aggggcatgt	720
acatcctaca	ggtgttagaa	aacgttacat	tttaatgagt	aacttcacta	gcacaataac	780
aatag						785

<210> 4  
<211> 1138  
<212> DNA  
<213> H. sapiens

<220>  
<221> Other  
<222> (395)...(482)

<400> 4

catctgttat	tttttgagtt	tttaataatg	gccattctga	ctggtgtgag	atggtatctc	60
tttgtggatt	taaccagtga	tgtaaacctt	tttttcatat	agtggtttgc	cacatatagt	120
tttcttttga	aaagtgtaac	aactttttta	atacttgaac	ttttcattga	ttatcttatt	180
tgtctaagct	actattttga	aaaatcatga	tttctttata	tacctaatta	tgaaattaag	240
gaaatgaaat	atgagtattc	tatttacatc	agtctgagta	gttcttggtt	cttaacatcc	300
cttggttctc	tcattgttaa	tctctttaga	tttctaacat	tctatgactt	ttgagttcca	360
ctcatggaat	aagatatatt	cttcactgta	acaggttctg	tggagatttg	atgggaataa	420
accagatact	ttaggactca	atactcggct	gtacaagtgg	ataccccaga	atgatcttct	480
tggttaagtct	ctgaagaaca	aatactgaat	atattagtaa	cagattatta	aagtgttaat	540



agctatcatg	aaacaagctt	actgaacatt	tggtatggaa	aaacttaaaa	ataaaatgaa	600
acttctttat	atthattttc	cagtcctggg	ggaaaagaat	aaattgttgg	cattttatga	660
tatgcaccca	cattctttac	aatcagagtc	agagtatctt	tatttcaggt	gttattacct	720
cccacagaat	ttttctggca	cttctctggg	tgtcttccct	tctcatattt	ctacaacttt	780
acacctgttc	tttctctctc	tgtagggtta	tttcaaagt	cactaaaagt	aacagctctt	840
ctgctatcac	cagggatgct	gcattttctg	taggattaaa	tccctaactc	taatcaaaaa	900
gtgatgacac	atthcataat	gaaatgtgac	ctgtctttcc	tcaattctag	caccaccacc	960
acctcactgc	ctgctgcctt	gcacacccta	catatccaac	tccgtgactg	tacttaagag	1020
aacacattct	ggctgggcac	ggtgctcacg	cctgcaatcc	tagcactttg	ggaggctgat	1080
ggcaggtgga	ttgactgagc	tcaggagttc	aagaccatcc	tgggcaacat	ggtgaaac	1138

<210> 5  
 <211> 689  
 <212> DNA  
 <213> H. sapiens  
 <220>  
 <221> Other  
 <222> (123)... (342)

<400> 5						
aaaaacaatt	ttaattcagt	tcagtgtgtt	atctaggaaa	caccgtcaca	ttcagattct	60
tccattgtgc	atthctcatt	ttattcctat	gaataattht	gctaaaattc	atccaatcct	120
aggtcaccca	aaaaccagag	cttttataac	tcatgttgga	gccaatggca	tctatgaggc	180
aatctaccat	ggaatcccta	tgggtggcgt	tccattgttt	gcagatcaac	ctgataacat	240
tgcacacatg	aaggccaagg	gagcagctgt	tagtttggac	ttccacacaa	tgtcgagtac	300
agacttactc	aatgcactga	agacagtaat	taatgatcct	ttgtgagtat	aacttttttt	360
ttactcgggt	gtcttttatg	ataggttccc	ttgtgaatag	tgagtatgac	ttttatcctt	420
tttataagcg	actgatttcg	aaagaattta	agtgatttaa	acaatctgaa	atctgctttt	480
atthtttgagt	ggttatttta	aaatthttat	tgaaccacat	acattttaatg	aataatcaat	540
tattgaaata	atthttctaca	caaaaataat	tttaaaagtga	tatagataag	aagacatttt	600
aaaataaatt	tgacgtaatc	aatccacagt	agaaaaggaaa	gataaaacttg	acgtaatata	660
ataaaatatt	ttaattcaat	atctaaaat				689

<210> 6  
 <211> 1589  
 <212> DNA  
 <213> H. sapiens  
 <220>  
 <221> Other  
 <222> (731)... (1475)

<400> 6						
atgcttaagc	aatgggtagc	ctttcttcat	gatgtgatta	tttcacactg	cagcctgtat	60
caaaacatct	catgcacctc	atagaaaaat	accctacta	tgtaaccaca	aaaactaaaa	120
attaaaagaa	aataaaattg	ctcatatgtt	ctctgcctca	aataattaac	tttctcacct	180
gacctccat	ttttacttta	aaaatattht	tcaattatga	aattccaatt	taaaagccaa	240
actttctatg	atgactcaaa	ttaaaataca	cacattctat	gtcaattcta	tgacatttac	300
tttgaatgat	ctggcacttt	aaaaaccttt	cgtggacttg	atgtgctcag	gcaaattaac	360
ttacctctc	tttttttgag	agggaaagtct	cactctgtca	ccaggctgga	gtgcagtggg	420
gtgattgtgg	ctcactgcaa	cttccgcctc	ttgggttcaa	gcgattctcc	tgctcagcc	480
tctcaagtag	ctgggactac	aggcacatgc	caccacgcct	gggtaatctt	tttttttttt	540
ttttttttca	tatttttact	ggagacgggg	tgaacggggg	ttcaccgtgt	tagccaggat	600
ggtcttgatc	tctgacctc	gtgatccgcc	cgcctcgacc	tcgaaagtgt	ctgggattgc	660
agggtgtgagc	ctccgtgcct	ggccaaattg	acttactttc	aatgttgata	ctttctgct	720
tatcgtttag	atataaagag	aatgctatga	aattatcaag	aattcatcat	gatcaaccag	780
tgaagcccct	tgatcgagca	gtcttctgga	ttgaatttgt	catgcgccat	aaaggagcca	840
agcaccttcg	ggttgacgcc	cacgacctca	cctggttcca	gtaccactct	ttggatgtga	900
ctgggttctc	gctggcctgt	gtggcaactg	tgatattcat	catcacaaaa	tgtctgtttt	960
gtgtctggaa	gtttgttaga	acaggaaaag	aggggaaaag	agattaatta	cgtctgaggc	1020
tggagctggg	gaaacccaat	aaatgaactc	ctttagttha	ttacaacaag	aagacgttgt	1080

```

gatacaagag attcctttct tcttgtgaca aaacatcttt caaaacttac cttgtcaagt 1140
caaaatttgt tttagtacct gtttaaccat tagaaatatt tcatgtcaag gaggaaaaca 1200
ttagggaaaa caaaaatgat ataaagccat acgagggttat attgaaatgt attgagctta 1260
tattgaaatt tattgttcca attcacaggt tacatgaaaa aaaatttact aagcttaact 1320
acatgtcaca cattgtacat ggaaacaaga acattaagaa gtccactgac agtatcagta 1380
ctgttttgca aatactcagc atactttgga tccatttcat gcaggattgt gttgttttaa 1440
ctgttgttga ggaaactaat aaataattaa attgtataga aagtctcttc ctcttgatat 1500
tttgagatga ttagtgctgc ttggctttta ttgtgcatcg tgcttcaacg tcattttttt 1560
tcctaaaagg tatgataaaa aatgcttac 1589

```

<210> 7  
 <211> 2092  
 <212> DNA  
 <213> H. sapiens

<220>  
 <221> CDS  
 <222> (38)...(1621)

```

<400> 7
agcagcaact ggaaaacaag cattgcattg catcagg atg tct atg aaa tgg act 55
                               Met Ser Met Lys Trp Thr
                               1       5

tca gct ctt ctg ctg ata cag ctg agc tgt tac ttt agc tct ggg agt 103
Ser Ala Leu Leu Leu Ile Gln Leu Ser Cys Tyr Phe Ser Ser Gly Ser
          10              15              20

tgt gga aag gtg ctg gtg tgg ccc aca gaa ttc agc cac tgg atg aat 151
Cys Gly Lys Val Leu Val Trp Pro Thr Glu Phe Ser His Trp Met Asn
          25              30              35

ata aag aca atc ctg gat gaa ctt gtc cag aga ggt cat gag gtg act 199
Ile Lys Thr Ile Leu Asp Glu Leu Val Gln Arg Gly His Glu Val Thr
          40              45              50

gta ttg gca tct tca gct tcc att tct ttc gat ccc aac agc cca tct 247
Val Leu Ala Ser Ser Ala Ser Ile Ser Phe Asp Pro Asn Ser Pro Ser
          55              60              65              70

act ctt aaa ttt gaa gtt tat cct gta tct tta act aaa act gag ttt 295
Thr Leu Lys Phe Glu Val Tyr Pro Val Ser Leu Thr Lys Thr Glu Phe
          75              80              85

gag gat att atc aag cag ctg gtt aag aga tgg gca gaa ctt cca aaa 343
Glu Asp Ile Ile Lys Gln Leu Val Lys Arg Trp Ala Glu Leu Pro Lys
          90              95              100

gac aca ttt tgg tca tat ttt tca caa gta caa gaa atc atg tgg aca 391
Asp Thr Phe Trp Ser Tyr Phe Ser Gln Val Gln Glu Ile Met Trp Thr
          105              110              115

ttt aat gac ata ctt aga aag ttc tgt aag gat ata gtt tca aat aag 439
Phe Asn Asp Ile Leu Arg Lys Phe Cys Lys Asp Ile Val Ser Asn Lys
          120              125              130

aaa ctt atg aag aaa cta cag gag tca aga ttt gat gtt gtt ctt gca 487
Lys Leu Met Lys Lys Leu Gln Glu Ser Arg Phe Asp Val Val Leu Ala
          135              140              145              150

gat gct gtt ttc ccc ttt ggt gag ctg ctg gcc gag tta ctt aaa ata 535
Asp Ala Val Phe Pro Phe Gly Glu Leu Leu Ala Glu Leu Leu Lys Ile

```

-5-

aag gcc aag gga gca gct gtt agt ttg gac ttc cac aca atg tcg agt 1303  
 Lys Ala Lys Gly Ala Ala Val Ser Leu Asp Phe His Thr Met Ser Ser  
 410 415 420  
 aca gac tta ctc aat gca ctg aag aca gta att aat gat cct tta tat 1351  
 Thr Asp Leu Leu Asn Ala Leu Lys Thr Val Ile Asn Asp Pro Leu Tyr  
 425 430 435  
 aaa gag aat gct atg aaa tta tca aga att cat cat gat caa cca gtg 1399  
 Lys Glu Asn Ala Met Lys Leu Ser Arg Ile His His Asp Gln Pro Val  
 440 445 450  
 aag ccc ctt gat cga gca gtc ttc tgg att gaa ttt gtc atg cgc cat 1447  
 Lys Pro Leu Asp Arg Ala Val Phe Trp Ile Glu Phe Val Met Arg His  
 455 460 465 470  
 aaa gga gcc aag cac ctt cgg gtt gca gcc cac gac ctc acc tgg ttc 1495  
 Lys Gly Ala Lys His Leu Arg Val Ala Ala His Asp Leu Thr Trp Phe  
 475 480 485  
 cag tac cac tct ttg gat gtg act ggg ttc ctg ctg gcc tgt gtg gca 1543  
 Gln Tyr His Ser Leu Asp Val Thr Gly Phe Leu Leu Ala Cys Val Ala  
 490 495 500  
 act gtg ata ttc atc atc aca aaa tgt ctg ttt tgt gtc tgg aag ttt 1591  
 Thr Val Ile Phe Ile Ile Thr Lys Cys Leu Phe Cys Val Trp Lys Phe  
 505 510 515  
 gtt aga aca gga aag aag ggg aaa aga gat taattacgtc tgaggctgga 1641  
 Val Arg Thr Gly Lys Lys Gly Lys Arg Asp  
 520 525  
 agctgggaaa cccaataaat gaactccttt agttttattac aacaagaaga cgttgtgata 1701  
 caagagattc ctttcttctt gtgacaaaac atctttcaaa acttaccttg tcaagtcaaa 1761  
 atttggttta gtacctgttt aaccattaga aatatttcat gtcaaggagg aaaacattag 1821  
 ggaaaacaaa aatgatataa agccatacga gggttatattg aaatgtattg agcttatatt 1881  
 gaaattttatt gttccaattc acaggttaca tgaaaaaaa tttactaagc ttaactacat 1941  
 gtcacacatt gtacatggaa acaagaacat taagaagtcc actgacagta tcagtactgt 2001  
 tttgcaaata ctcagcatatc tttggatcca tttcatgcag gattgtgttg ttttaactgt 2061  
 tgttgaggaa actaataaat aattaaattg t 2092

<210> 8  
 <211> 528  
 <212> PRT  
 <213> H. sapiens

<400> 8  
 Met Ser Met Lys Trp Thr Ser Ala Leu Leu Leu Ile Gln Leu Ser Cys  
 1 5 10 15  
 Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp Pro Thr Glu  
 20 25 30  
 Phe Ser His Trp Met Asn Ile Lys Thr Ile Leu Asp Glu Leu Val Gln  
 35 40 45  
 Arg Gly His Glu Val Thr Val Leu Ala Ser Ser Ala Ser Ile Ser Phe  
 50 55 60  
 Asp Pro Asn Ser Pro Ser Thr Leu Lys Phe Glu Val Tyr Pro Val Ser  
 65 70 75 80  
 Leu Thr Lys Thr Glu Phe Glu Asp Ile Ile Lys Gln Leu Val Lys Arg  
 85 90 95  
 Trp Ala Glu Leu Pro Lys Asp Thr Phe Trp Ser Tyr Phe Ser Gln Val  
 100 105 110  
 Gln Glu Ile Met Trp Thr Phe Asn Asp Ile Leu Arg Lys Phe Cys Lys

115	120	125
Asp Ile Val Ser Asn Lys Lys Leu Met Lys Lys Leu Gln Glu Ser Arg		
130	135	140
Phe Asp Val Val Leu Ala Asp Ala Val Phe Pro Phe Gly Glu Leu Leu		
145	150	155
Ala Glu Leu Leu Lys Ile Pro Phe Val Tyr Ser Leu Arg Phe Ser Pro		
165	170	175
Gly Tyr Ala Ile Glu Lys His Ser Gly Gly Leu Leu Phe Pro Pro Ser		
180	185	190
Tyr Val Pro Val Val Met Ser Glu Leu Ser Asp Gln Met Thr Phe Ile		
195	200	205
Glu Arg Val Lys Asn Met Ile Tyr Val Leu Tyr Phe Glu Phe Trp Phe		
210	215	220
Gln Ile Phe Asp Met Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val Leu		
225	230	235
Gly Arg Pro Thr Thr Leu Ser Glu Thr Met Ala Lys Ala Asp Ile Trp		
245	250	255
Leu Ile Arg Asn Tyr Trp Asp Phe Gln Phe Pro His Pro Leu Leu Pro		
260	265	270
Asn Val Glu Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Pro Leu		
275	280	285
Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly Glu Asn Gly Val		
290	295	300
Val Val Phe Ser Leu Gly Ser Met Val Ser Asn Thr Ser Glu Glu Arg		
305	310	315
Ala Asn Val Ile Ala Ser Ala Leu Ala Lys Ile Pro Gln Lys Val Leu		
325	330	335
Trp Arg Phe Asp Gly Asn Lys Pro Asp Thr Leu Gly Leu Asn Thr Arg		
340	345	350
Leu Tyr Lys Trp Ile Pro Gln Asn Asp Leu Leu Gly His Pro Lys Thr		
355	360	365
Arg Ala Phe Ile Thr His Gly Gly Ala Asn Gly Ile Tyr Glu Ala Ile		
370	375	380
Tyr His Gly Ile Pro Met Val Gly Val Pro Leu Phe Ala Asp Gln Pro		
385	390	395
Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Val Ser Leu Asp		
405	410	415
Phe His Thr Met Ser Ser Thr Asp Leu Leu Asn Ala Leu Lys Thr Val		
420	425	430
Ile Asn Asp Pro Leu Tyr Lys Glu Asn Ala Met Lys Leu Ser Arg Ile		
435	440	445
His His Asp Gln Pro Val Lys Pro Leu Asp Arg Ala Val Phe Trp Ile		
450	455	460
Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Val Ala Ala		
465	470	475
His Asp Leu Thr Trp Phe Gln Tyr His Ser Leu Asp Val Thr Gly Phe		
485	490	495
Leu Leu Ala Cys Val Ala Thr Val Ile Phe Ile Ile Thr Lys Cys Leu		
500	505	510
Phe Cys Val Trp Lys Phe Val Arg Thr Gly Lys Lys Gly Lys Arg Asp		
515	520	525

<210> 9  
 <211> 24  
 <212> DNA  
 <213> H. sapiens

<400> 9  
 taccttttag ttgtctcttt gtca

24

<210> 10  
 <211> 21

<212> DNA	
<213> H. sapiens	
<400> 10	
ttcctggagt cttctgtatg a	21
<210> 11	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 11	
catcccttgt tcttctcatt	20
<210> 12	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 12	
cgggactgga aaataaatat	20
<210> 13	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 13	
gggggtttcac cgtgtta	17
<210> 14	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 14	
aaagccaagc agcactaa	18
<210> 15	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 15	
ccacatgctc agactgttaa	20
<210> 16	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 16	
caaaaatacc ccactaccc	19
<210> 17	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 17	
cccttgttct tctcattgtt a	21

<210> 18	
<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 18	
ttcagtaagc ttgtttcatg at	22
<210> 19	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 19	
cctggccaaa ttgactt	17
<210> 20	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 20	
caggaaccca gtcacatc	18
<210> 21	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 21	
ggggaaaaga gattaattac g	21
<210> 22	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 22	
agccaagcag cactaatc	18
<210> 23	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 23	
tccaattcac aggttacatg	20
<210> 24	
<211> 18	
<212> DNA	
<213> H. sapiens	
<400> 24	
agccaagcag cactaatc	18
<210> 25	
<211> 27	
<212> DNA	
<213> H. sapiens	
<400> 25	

tgatgaata taaagacaat cctggat 27  
    <210> 26  
    <211> 27  
    <212> DNA  
    <213> H. sapiens  
    <400> 26  
tgatgaata taaacacaat cctggat 27  
    <210> 27  
    <211> 27  
    <212> DNA  
    <213> H. sapiens  
    <400> 27  
aagtgttaat agttatcatg aaacaag 27  
    <210> 28  
    <211> 27  
    <212> DNA  
    <213> H. sapiens  
    <400> 28  
aagtgttaat agctatcatg aaacaag 27  
    <210> 29  
    <211> 27  
    <212> DNA  
    <213> H. sapiens  
    <400> 29  
tgaagcccct tgatcgagca gtcttct 27  
    <210> 30  
    <211> 27  
    <212> DNA  
    <213> H. sapiens  
    <400> 30  
tgaagcccct tgaacgagca gtcttct 27  
    <210> 31  
    <211> 27  
    <212> DNA  
    <213> H. sapiens  
    <400> 31  
tgaagcccct tgatcgagca gtcttct 27  
    <210> 32  
    <211> 27  
    <212> DNA  
    <213> H. sapiens  
    <400> 32  
tgaagcccct tgatagagca gtcttct 27  
    <210> 33  
    <211> 27  
    <212> DNA  
    <213> H. sapiens



<400> 33  
 gatataaagc catacgaggt tatattg 27  
 <210> 34  
 <211> 27  
 <212> DNA  
 <213> H. sapiens

<400> 34  
 gatataaagc catatgaggt tatattg 27  
 <210> 35  
 <211> 26  
 <212> DNA  
 <213> H. sapiens

<400> 35  
 caggttacat gaaaaaaaat ttacta 26  
 <210> 36  
 <211> 26  
 <212> DNA  
 <213> H. sapiens

<400> 36  
 caggttacat gaaaaacaat ttacta 26  
 <210> 37  
 <211> 27  
 <212> DNA  
 <213> H. sapiens

<400> 37  
 ttgttgagga agctaataaa taattaa 27  
 <210> 38  
 <211> 27  
 <212> DNA  
 <213> H. sapiens

<400> 38  
 ttgttgagga aactaataaa taattaa 27  
 <210> 39  
 <211> 1854  
 <212> DNA  
 <213> H. sapiens

<220>  
 <221> CDS  
 <222> (15)...(1584)

<400> 39  
 tgcattgcac cagg atg tct gtg aaa tgg act tca gta att ttg cta ata 50  
                   Met Ser Val Lys Trp Thr Ser Val Ile Leu Leu Ile  
                   1                  5                  10

caa ctg agc ttt tgc ttt agc tct ggg aat tgt gga aag gtg ctg gtg 98  
 Gln Leu Ser Phe Cys Phe Ser Ser Gly Asn Cys Gly Lys Val Leu Val  
           15                  20                  25

tgg gca gca gaa tac agc cat tgg atg aat ata aag aca atc ctg gat	146
Trp Ala Ala Glu Tyr Ser His Trp Met Asn Ile Lys Thr Ile Leu Asp	
30 35 40	
gag ctt att cag aga ggt cat gag gtg act gta ctg gca tct tca gct	194
Glu Leu Ile Gln Arg Gly His Glu Val Thr Val Leu Ala Ser Ser Ala	
45 50 55 60	
tcc att ctt ttt gat ccc aac aac tca tcc gct ctt aaa att gaa att	242
Ser Ile Leu Phe Asp Pro Asn Asn Ser Ser Ala Leu Lys Ile Glu Ile	
65 70 75	
tat ccc aca tct tta act aaa act gag ttg gag aat ttc atc atg caa	290
Tyr Pro Thr Ser Leu Thr Lys Thr Glu Leu Glu Asn Phe Ile Met Gln	
80 85 90	
cag att aag aga tgg tca gac ctt cca aaa gat aca ttt tgg tta tat	338
Gln Ile Lys Arg Trp Ser Asp Leu Pro Lys Asp Thr Phe Trp Leu Tyr	
95 100 105	
ttt tca caa gta cag gaa atc atg tca ata ttt ggt gac ata act aga	386
Phe Ser Gln Val Gln Glu Ile Met Ser Ile Phe Gly Asp Ile Thr Arg	
110 115 120	
aag ttc tgt aaa gat gta gtt tca aat aag aaa ttt atg aaa aaa gta	434
Lys Phe Cys Lys Asp Val Val Ser Asn Lys Lys Phe Met Lys Lys Val	
125 130 135 140	
caa gag tca aga ttt gac gtc att ttt gca gat gct att ttt ccc tgt	482
Gln Glu Ser Arg Phe Asp Val Ile Phe Ala Asp Ala Ile Phe Pro Cys	
145 150 155	
agt gag ctg ctg gct gag cta ttt aac ata ccc ttt gtg tac agt ctc	530
Ser Glu Leu Leu Ala Glu Leu Phe Asn Ile Pro Phe Val Tyr Ser Leu	
160 165 170	
agc ttc tct cct ggc tac act ttt gaa aag cat agt gga gga ttt att	578
Ser Phe Ser Pro Gly Tyr Thr Phe Glu Lys His Ser Gly Gly Phe Ile	
175 180 185	
ttc cct cct tcc tac gta cct gtt gtt atg tca gaa tta act gat caa	626
Phe Pro Pro Ser Tyr Val Pro Val Val Met Ser Glu Leu Thr Asp Gln	
190 195 200	
atg act ttc atg gag agg gta aaa aat atg atc tat gtg ctt tac ttt	674
Met Thr Phe Met Glu Arg Val Lys Asn Met Ile Tyr Val Leu Tyr Phe	
205 210 215 220	
gac ttt tgg ttc gaa ata ttt gac atg aag aag tgg gat cag ttt tat	722
Asp Phe Trp Phe Glu Ile Phe Asp Met Lys Lys Trp Asp Gln Phe Tyr	
225 230 235	
agt gaa gtt cta gga aga ccc act aca tta tct gag aca atg ggg aaa	770
Ser Glu Val Leu Gly Arg Pro Thr Thr Leu Ser Glu Thr Met Gly Lys	
240 245 250	
gct gac gta tgg ctt att cga aac tcc tgg aat ttt cag ttt cca tat	818
Ala Asp Val Trp Leu Ile Arg Asn Ser Trp Asn Phe Gln Phe Pro Tyr	
255 260 265	
cca ctc tta cca aat gtt gat ttt gtt gga gga ctc cac tgc aaa cct	866
Pro Leu Leu Pro Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro	

270	275	280	
gcc aaa ccc ctg cct aag gaa atg gaa gac ttt gta cag agc tct gga Ala Lys Pro Leu Pro Lys Glu Met Glu Asp Phe Val Gln Ser Ser Gly 285 290 295 300			914
gaa aat ggt gtt gtg gtg ttt tct ctg ggg tca atg gtc agt aac atg Glu Asn Gly Val Val Val Phe Ser Leu Gly Ser Met Val Ser Asn Met 305 310 315			962
aca gaa gaa agg gcc aac gta att gca tca gcc ctg gcc cag atc cca Thr Glu Glu Arg Ala Asn Val Ile Ala Ser Ala Leu Ala Gln Ile Pro 320 325 330			1010
caa aag gtt ctg tgg aga ttt gat ggg aat aaa cca gat acc tta ggt Gln Lys Val Leu Trp Arg Phe Asp Gly Asn Lys Pro Asp Thr Leu Gly 335 340 345			1058
ctc aat act cgg ctc tac aag tgg ata ccc cag aat gac ctt cta ggt Leu Asn Thr Arg Leu Tyr Lys Trp Ile Pro Gln Asn Asp Leu Leu Gly 350 355 360			1106
cat cca aag acc aga gct ttt ata act cat ggt gga gcc aat ggc atc His Pro Lys Thr Arg Ala Phe Ile Thr His Gly Gly Ala Asn Gly Ile 365 370 375 380			1154
tac gag gca atc tac cat ggg atc cct atg gtg ggg att cca ttg ttt Tyr Glu Ala Ile Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe 385 390 395			1202
gcc gat caa cct gat aac att gct cac atg aag gcc agg gga gca gct Ala Asp Gln Pro Asp Asn Ile Ala His Met Lys Ala Arg Gly Ala Ala 400 405 410			1250
gtt aga gtg gac ttc aac aca atg tcg agt aca gac ttg ctg aat gca Val Arg Val Asp Phe Asn Thr Met Ser Ser Thr Asp Leu Leu Asn Ala 415 420 425			1298
ttg aag aga gta att aat gat cct tca tat aaa gag aat gtt atg aaa Leu Lys Arg Val Ile Asn Asp Pro Ser Tyr Lys Glu Asn Val Met Lys 430 435 440			1346
tta tca aga att caa cat gat caa cca gtg aag ccc ctg gat cga gca Leu Ser Arg Ile Gln His Asp Gln Pro Val Lys Pro Leu Asp Arg Ala 445 450 455 460			1394
gtc ttc tgg att gaa ttt gtc atg cgc cac aaa gga gct aaa cac ctt Val Phe Trp Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu 465 470 475			1442
cgg gtt gca gcc cac gac ctc acc tgg ttc cag tac cac tct ttg gat Arg Val Ala Ala His Asp Leu Thr Trp Phe Gln Tyr His Ser Leu Asp 480 485 490			1490
gtg att ggg ttc ctg ctg gtc tgt gtg gca act gtg ata ttt atc gtc Val Ile Gly Phe Leu Leu Val Cys Val Ala Thr Val Ile Phe Ile Val 495 500 505			1538
aca aaa tgt tgt ctg ttt tgt ttc tgg aag ttt gct aga aaa gca a Thr Lys Cys Cys Leu Phe Cys Phe Trp Lys Phe Ala Arg Lys Ala 510 515 520			1584

```

agaagggaaa aaatgattag ttatatctga gatttgaagc tggaaaacct gataggtgag 1644
actacttcag tttattccag caagaaagat tgtgatgcaa gatttctttc ttcctgagac 1704
aaaaaaaaaa aaagaaaaaa aaatcttttc aaaatttact ttgtcaaata aaaatttggt 1764
tttcagagat ttaccaccca gttcatgggt agaaatattt tgtggcaatg aagaaaacac 1824
tacggaaaat aaaaaataag ataaagcctt                                     1854

```

&lt;210&gt; 40

&lt;211&gt; 524

&lt;212&gt; PRT

&lt;213&gt; H. sapiens

&lt;400&gt; 40

```

Met Ser Val Lys Trp Thr Ser Val Ile Leu Leu Ile Gln Leu Ser Phe
 1      5      10      15
Cys Phe Ser Ser Gly Asn Cys Gly Lys Val Leu Val Trp Ala Ala Glu
 20      25      30
Tyr Ser His Trp Met Asn Ile Lys Thr Ile Leu Asp Glu Leu Ile Gln
 35      40      45
Arg Gly His Glu Val Thr Val Leu Ala Ser Ser Ala Ser Ile Leu Phe
 50      55      60
Asp Pro Asn Asn Ser Ser Ala Leu Lys Ile Glu Ile Tyr Pro Thr Ser
 65      70      75      80
Leu Thr Lys Thr Glu Leu Glu Asn Phe Ile Met Gln Gln Ile Lys Arg
 85      90      95
Trp Ser Asp Leu Pro Lys Asp Thr Phe Trp Leu Tyr Phe Ser Gln Val
100      105      110
Gln Glu Ile Met Ser Ile Phe Gly Asp Ile Thr Arg Lys Phe Cys Lys
115      120      125
Asp Val Val Ser Asn Lys Lys Phe Met Lys Lys Val Gln Glu Ser Arg
130      135      140
Phe Asp Val Ile Phe Ala Asp Ala Ile Phe Pro Cys Ser Glu Leu Leu
145      150      155      160
Ala Glu Leu Phe Asn Ile Pro Phe Val Tyr Ser Leu Ser Phe Ser Pro
165      170      175
Gly Tyr Thr Phe Glu Lys His Ser Gly Gly Phe Ile Phe Pro Pro Ser
180      185      190
Tyr Val Pro Val Val Met Ser Glu Leu Thr Asp Gln Met Thr Phe Met
195      200      205
Glu Arg Val Lys Asn Met Ile Tyr Val Leu Tyr Phe Asp Phe Trp Phe
210      215      220
Glu Ile Phe Asp Met Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val Leu
225      230      235      240
Gly Arg Pro Thr Thr Leu Ser Glu Thr Met Gly Lys Ala Asp Val Trp
245      250      255
Leu Ile Arg Asn Ser Trp Asn Phe Gln Phe Pro Tyr Pro Leu Leu Pro
260      265      270
Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Pro Leu
275      280      285
Pro Lys Glu Met Glu Asp Phe Val Gln Ser Ser Gly Glu Asn Gly Val
290      295      300
Val Val Phe Ser Leu Gly Ser Met Val Ser Asn Met Thr Glu Glu Arg
305      310      315      320
Ala Asn Val Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val Leu
325      330      335
Trp Arg Phe Asp Gly Asn Lys Pro Asp Thr Leu Gly Leu Asn Thr Arg
340      345      350
Leu Tyr Lys Trp Ile Pro Gln Asn Asp Leu Leu Gly His Pro Lys Thr
355      360      365
Arg Ala Phe Ile Thr His Gly Gly Ala Asn Gly Ile Tyr Glu Ala Ile
370      375      380
Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe Ala Asp Gln Pro
385      390      395      400

```

```
<210> 42
<211> 1340
<212> DNA
<213> H. sapiens
```

<220>  
 <221> exon  
 <222> (668) ... (816)

<400> 42

atagtttttg	gaactaggcc	cctttattag	aacatatgag	acaattaagg	tggagtacaa	60
tttttatttc	ataatttctc	aaaaatttct	agctataatg	tacaaatata	tttacttaaa	120
aatattatta	agatcttagc	ttgaatctaa	aagagtagtt	ggtacaagga	tttcagccat	180
actctcaaca	tagtccacag	ttcacttgaa	ccaaagataa	aagaattagc	ttaatgagtt	240
gtgtaaaact	gactatttct	tagaaaatta	tttttatggg	tagagtagaa	ttaattgatt	300
atggagctca	aagagttggt	taaatgtccg	tatgctacta	ttgaagcttt	aagagaaaag	360
aaattttatg	tttaactttc	tatggctcat	tttaataatt	gtttatgatt	atgagcatac	420
tgatgcgaca	ttagagatgt	agcttaacct	cacaattctc	ctactacttt	gtctttctta	480
taaatacaca	tgggcaaaat	atgtaataca	taaaattaaa	ttatatctat	atatgaatat	540
gtgtatatat	ttttcaaagc	acagatatct	gcctacattt	ttgcctacat	tattctaacc	600
cctttcagaa	atttacctaa	agtaattatc	ttgtgtcatc	cacctttttt	ttttctattc	660
ctgtcaggaa	gacccactac	attatctgag	acaatgggga	aagctgacgt	atggcttatt	720
cgaaactcct	ggaattttca	gtttccatat	ccactcttac	caaagtgtga	ttttgttggg	780
ggactccact	gcaaacctgc	caaaccctcg	cctaaggtaa	acatactttt	gttggtttta	840
ttttgttggc	tttgaatttt	cagtagaaat	gattctatag	tcttctttca	gagtgtttga	900
cttacactga	aagaaagatg	ggaaatgggt	ggggtaaagc	agataccaat	tagaaactca	960
tgtgcacgtt	aataccatca	cacgtatatg	agttttatga	gtattacaaa	tagagaggaa	1020
tactaaggag	actttgaaaa	tagggttggt	taaattaaag	tcttcattat	gcaataccta	1080
agaaggtatt	ggtcattccaa	tcaataataa	tttacaaagg	gattagcaca	aaacacaggt	1140
aagtgcagaa	ttttcagaga	aaaaaataga	cacagtttct	gtccccacat	accttacatt	1200
ctacttcaaa	agatagaata	tgtgcaagta	ataaaaacta	tataaaaact	attatctgaa	1260
ggaaaaacgc	aataccaaga	aagcatcagt	ggagataata	gaaagtatcc	tgcagtcact	1320
gattagtaag	atgggtaccg					1340

<210> 43  
 <211> 1822  
 <212> DNA  
 <213> H. sapiens

<220>  
 <221> exon  
 <222> (732) ... (863)

<400> 43

tatatacaat	gtctgtatga	taaatgagac	tctctggcact	aattcataga	aattccaaat	60
tacattacca	gactccagaa	tgtcagcggt	tcttaaccac	cagcttttat	ttattttatt	120
tttttttagt	tttgaaaaac	taccagaaaa	ctctgaacaa	actttaagtg	aagtataaag	180
cattgtagag	aaacataaat	gtagatataa	aattatccca	actgtgagta	gcttatcctc	240
agagctcata	gttagggaag	taaaccacta	actgtttcca	actaagagaa	ttctacagaa	300
aacctgcctg	aaataaacac	aagggattta	gtagaacaac	aatataggat	taaagctgag	360
tgggtccact	ttccaagaac	ctatatattg	aacttttagt	atgaaaagtg	agagtctgtg	420
attaatatat	ttaacattat	ctccctgaca	acaatgtaat	agctccattt	cttttctccc	480
ttacacacat	gcacacaaat	acatacacat	acacacatat	ttacacaaat	atccttaaca	540
gcatccacct	atctcatatt	atacatctac	ttgcaaaaaa	actgagtgat	tgggtcagtt	600
aaaaaatatt	attttactca	ataattcttc	aaaatactgg	attttctctc	tttagtaatt	660
tgcaccaatt	cttttggtag	tgcccgctgt	gctaatactc	ttttgtgatg	aagcaaattc	720
tttcttcaca	ggaaatggaa	gactttgtac	agagctctgg	agaaaaagtg	gttgtggtgt	780
tttctctggg	gtcaatggtc	agtaacatga	cagaagaaag	ggccaacgta	attgcatcag	840
ccctggccca	gatccacaaa	aaggtaagat	gaagtgcctt	actggtgtgg	aaaactactg	900
aaagaggctg	ttaaagtttg	aagtaatcca	attatagaaa	cttctgataa	atgtgaagtt	960
gaccaaaagt	tgaaaaaatta	gaacaaggat	aatcttgag	aaactatgag	aagtttgaaa	1020
attgtggttg	catttttttt	taaatgggtg	taagtatgaa	cattccctta	tgtaaaatag	1080
ctgacaataa	attgaatgga	gaaaggtatt	taaaaagtg	ttggagactt	ctcacctcct	1140
gtccataaaa	ttttgaattg	tgtatgtgat	ctacatagga	aaggatatta	aagagttagat	1200
tgaactcttc	catagctgaa	tatagcctta	aatatgcttg	tatagcatcc	accgacagaa	1260
gtaaatagttg	tgcctcagac	ttgggggttg	catgtggccc	tggaggagtt	actacccttg	1320
gtatgcatga	gtagttccta	ttagcatcag	tgggaactca	gtactccata	tgtattcaca	1380

aaaggcaact	tgagaccac	agttatTTTT	aatttctgat	attaacactc	atacatactg	1440
ctgaatttaa	ctcaatatat	ttcagttaag	tgaaaatggg	gcttaatgta	gtcttttagaa	1500
tgactttcag	gtgttttcac	aaaaaacgta	tatccagaac	tgtgtccttt	tagaaataca	1560
agtaaaattt	ttgataatta	gcttcaaaac	agttttccta	atctcagcag	tatccaatga	1620
gtgaagaaca	cttgactgac	tcttggtgca	cctctattac	ttattgtact	ctggaagctc	1680
ttggtgaatg	tttacgatta	tgggatgtag	tatttctggt	tgcaacttaa	gtcaaagtgt	1740
tgtataaaat	acgtgacaac	aaatggagaa	tattggctct	gtagtagatt	atgcggtata	1800
ttctctgttt	aaggatcttt	gg				1822

&lt;210&gt; 44

&lt;211&gt; 1591

&lt;212&gt; DNA

&lt;213&gt; H. sapiens

&lt;220&gt;

&lt;221&gt; exon

&lt;222&gt; (138) ... (225)

&lt;221&gt; exon

&lt;222&gt; (1067) ... (1286)

&lt;400&gt; 44

attctattta	cattagcctt	tgagtagttc	ttatttacta	acatcccttg	atctcattcc	60
tactctttat	acagttctca	cattctataa	cttttgaatt	ccactcatgg	aataaaatat	120
tttctttatt	gtaacagggt	ctgtggagat	ttgatgggaa	taaaccagat	accttaggtc	180
tcaatactcg	gctctacaag	tgatacccc	agaatgacct	tctaggtaag	actctggtga	240
acaaatactg	aatatattag	taacagcaca	ttagagtgtt	aatagttcat	catgaaacaa	300
gcttattgaa	tatttgtaa	ggaaaaacaa	aatgtaactt	ctttatattg	attttccagt	360
cttaaggagg	aaagaatata	ttataatttt	tggcatttta	tgatatacac	ccacattcct	420
tatagtctga	atcgggggaa	tctttatttc	aggtgttatt	atatctcaca	aaatttttca	480
ataacttcoct	gggctgtctc	tctgtctcct	atttctacaa	ctttacacct	gtttttttcc	540
tctcccgcag	ggttatttga	aatgccacta	aaaataatag	ctcttctatc	accagtgact	600
ctgtattttc	tgaagaatta	aactgctaata	cttaatcata	cagtgatgat	acatttcacg	660
atgaagtgtg	acctgtcctt	cctcaatcct	agcaccacca	ccaaaccact	gcctgctgcc	720
ttgcccaccc	catatatcac	actctgtgac	tgctcactta	aataagagtt	cacttcatgc	780
ctatctcttt	gctgtcttct	tttttgacaa	tttttgaaat	ctagaatgca	atttttcatt	840
agcccaactg	gaaatcttgt	attgttttgc	agtctgaagt	cacacacacc	gtatagcctt	900
cagttacata	cccagtacaa	gtacgtgttt	tttctccga	agtctgaaac	acaattttta	960
tttagttcag	tgtttttagct	ggaaaacact	gtcactttca	gagcctttca	ttgtgcatct	1020
cattttattc	ctatgagtaa	ttttgctaaa	attcatccaa	tcctagggtca	tccaaagacc	1080
agagctttta	taactcatgg	tggagccaat	ggcatctacg	aggcaatcta	ccatgggatc	1140
cctatggtgg	ggattccatt	gtttgccgat	caacctgata	acattgctca	catgaaggcc	1200
aggggagcag	ctgtagaggt	ggacttcaac	acaatgtcga	gtacagactt	gctgaatgca	1260
ttgaagagag	taattaatga	tccttcgtga	gtagaacaat	atttttcact	aggtggtatt	1320
tacagatagc	ttctcttgtc	aatagtgagt	gtgagtttca	tcctttttat	aagagactaa	1380
ttttgaaaga	atttaaatgat	ttaaccaatc	tgaatatctgc	ttttattttt	ataagttatt	1440
taaaaattga	atttgaaaca	catacatcta	aagaatagcc	agttagttaa	acaattttct	1500
acacaaaaat	aattttaaaa	ggatatagat	aatacaaaaa	atacatttct	taaaaatttg	1560
acataattaa	tccatagaag	aaaggaagaa	t			1591

&lt;210&gt; 45

&lt;211&gt; 596

&lt;212&gt; DNA

&lt;213&gt; H. sapiens

&lt;220&gt;

&lt;221&gt; exon

&lt;222&gt; (19) ... (549)

&lt;400&gt; 45

ctttattttt	atctttcaga	tataaagaga	atgttatgaa	attatcaaga	attcaacatg	60
atcaaccagt	gaagcccctg	gatcgagcag	tcttctggat	tgaatttgct	atgcgccaca	120

aaggagctaa	acaccttcgg	gttgcagccc	acgacctcac	ctggttccag	taccactctt	180
tggtatgtgat	tggttctctg	ctggtctgtg	tggaactgt	gatatttatc	gtcacaaaat	240
gttgtctgtt	ttgtttctgg	aagtttgcta	gaaaagcaaa	gaagggaaaa	aatgattagt	300
tatatctgag	atttgaagct	ggaaaacctg	ataggtgaga	ctacttcagt	ttattccagc	360
aagaaagatt	gtgatgcaag	atttctttct	tcctgagaca	aaaaaaaaaa	aagaaaaaaa	420
aatcttttca	aaatttactt	tgtcaaataa	aaatttggtt	ttcagagatt	taccaccag	480
ttcatgggta	gaaatatttt	gtggcaatga	agaaaacact	acggaaaata	aaaaataaga	540
taaagcctta	tgagctcgta	ttgaaatttg	ttgaacttat	atcgcggatc	ctactg	596

<210> 46  
 <211> 20  
 <212> DNA  
 <213> H. sapiens

<400> 46	
cttggctaatt	ttatctttgg
	20

<210> 47  
 <211> 19  
 <212> DNA  
 <213> H. sapiens

<400> 47	
cccactaccc	tgactttat
	19

<210> 48  
 <211> 20  
 <212> DNA  
 <213> H. sapiens

<400> 48	
ggacataacc	atgagaaatg
	20

<210> 49  
 <211> 19  
 <212> DNA  
 <213> H. sapiens

<400> 49	
agctctgctt	caaagacac
	19

<210> 50  
 <211> 21  
 <212> DNA  
 <213> H. sapiens

<400> 50	
tgtccgtatg	ctactattga a
	21

<210> 51  
 <211> 21  
 <212> DNA  
 <213> H. sapiens

<400> 51	
tgtgctaatac	cctttgtaaa t
	21

<210> 52  
 <211> 22  
 <212> DNA  
 <213> H. sapiens



<400> 52  
tttttttttc ttttcctgtc ag 22  
<210> 53  
<211> 17  
<212> DNA  
<213> H. sapiens

<400> 53  
ctttacccca cccattt 17  
<210> 54  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 54  
cccttgatct cattcctact 20  
<210> 55  
<211> 24  
<212> DNA  
<213> H. sapiens

<400> 55  
aactggctat tctttagatg tatg 24  
<210> 56  
<211> 25  
<212> DNA  
<213> H. sapiens

<400> 56  
cattcctact ctttatacag ttctc 25  
<210> 57  
<211> 17  
<212> DNA  
<213> H. sapiens

<400> 57  
cccccgattc agactat 17  
<210> 58  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 58  
cccttgatct cattcctact 20  
<210> 59  
<211> 24  
<212> DNA  
<213> H. sapiens

<400> 59  
aactggctat tctttagatg tatg 24  
<210> 60  
<211> 18  
<212> DNA

<213> H. sapiens

<400> 60  
tcctccgaag tctgaaac 18

<210> 61  
<211> 23  
<212> DNA  
<213> H. sapiens

<400> 61  
tataaaaagg atgaaactca cac 23

<210> 62  
<211> 18  
<212> DNA  
<213> H. sapiens

<400> 62  
caagcccca agttatgt 18

<210> 63  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 63  
cagtaggatc cgcgatataa 20

<210> 64  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 64  
tctgaggggt tttgtctgta 20

<210> 65  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 65  
ccgcgatata agttcaacaa 20

<210> 66  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 66  
ggacataacc atgagaaatg 20

<210> 67  
<211> 19  
<212> DNA  
<213> H. sapiens

<400> 67  
ttaagagcgg atgagttgt 19

<210> 68

<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 68	
tcatcatgca acagattaag	20
<210> 69	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 69	
cactacaggg aaaaatagca	20
<210> 70	
<211> 20	
<212> DNA	
<213> H. sapiens	
<400> 70	
accctttgtg tacagtctca	20
<210> 71	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 71	
agctctgctt caaagacac	19
<210> 72	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 72	
ttgcctacat tattctaacc c	21
<210> 73	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 73	
ctttacccca cccattt	17
<210> 74	
<211> 25	
<212> DNA	
<213> H. sapiens	
<400> 74	
cattcctact ctttatacag ttctc	25
<210> 75	
<211> 17	
<212> DNA	
<213> H. sapiens	
<400> 75	
ccccgattc agactat	17

<210> 76  
<211> 25  
<212> DNA  
<213> H. sapiens  
  
<400> 76  
cattcctact ctttatacag ttctc 25  
  
<210> 77  
<211> 17  
<212> DNA  
<213> H. sapiens  
  
<400> 77  
cccccgattc agactat 17  
  
<210> 78  
<211> 18  
<212> DNA  
<213> H. sapiens  
  
<400> 78  
tcctccgaag tctgaaac 18  
  
<210> 79  
<211> 23  
<212> DNA  
<213> H. sapiens  
  
<400> 79  
tataaaaagg atgaaactca cac 23  
  
<210> 80  
<211> 20  
<212> DNA  
<213> H. sapiens  
  
<400> 80  
tctgaggggt tttgtctgta 20  
  
<210> 81  
<211> 22  
<212> DNA  
<213> H. sapiens  
  
<400> 81  
ttttttgtct caggaagaaa ga 22  
  
<210> 82  
<211> 24  
<212> DNA  
<213> H. sapiens  
  
<400> 82  
aaaaaaaagaa aaaaaaatct ttct 24  
  
<210> 83  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 83  
ccgcgatata agttcaacaa 20  
    <210> 84  
    <211> 22  
    <212> DNA  
    <213> H. sapiens

<400> 84  
tgcattgcac caggatgtct gt 22  
    <210> 85  
    <211> 21  
    <212> DNA  
    <213> H. sapiens

<400> 85  
gcattgcacc aagatgtctg t 21  
    <210> 86  
    <211> 23  
    <212> DNA  
    <213> H. sapiens

<400> 86  
tcctggatga gcttattcag aga 23  
    <210> 87  
    <211> 23  
    <212> DNA  
    <213> H. sapiens

<400> 87  
tcctggatga gcctattcag aga 23  
    <210> 88  
    <211> 21  
    <212> DNA  
    <213> H. sapiens

<400> 88  
cattttgggtt atatttttca c 21  
    <210> 89  
    <211> 21  
    <212> DNA  
    <213> H. sapiens

<400> 89  
cattttgggtt ttatttttca c 21  
    <210> 90  
    <211> 21  
    <212> DNA  
    <213> H. sapiens

<400> 90  
cataactaga aagttctgta a 21  
    <210> 91  
    <211> 21  
    <212> DNA

<213> H. sapiens

<400> 91  
cataactagg aagttctgta a 21

<210> 92  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 92  
cctggctaca cttttgaaaa 20

<210> 93  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 93  
cctggctaca tttttgaaaa 20

<210> 94  
<211> 21  
<212> DNA  
<213> H. sapiens

<400> 94  
gaagaccac tacattatct g 21

<210> 95  
<211> 21  
<212> DNA  
<213> H. sapiens

<400> 95  
gaagaccac tacgttatct g 21

<210> 96  
<211> 26  
<212> DNA  
<213> H. sapiens

<400> 96  
aattttcagt ttccatatcc actctt 26

<210> 97  
<211> 26  
<212> DNA  
<213> H. sapiens

<400> 97  
aattttcagt ttctcatcc actctt 26

<210> 98  
<211> 22  
<212> DNA  
<213> H. sapiens

<400> 98  
taggtctcaa tactcggctc ta 22

<210> 99

<211> 22	
<212> DNA	
<213> H. sapiens	
<400> 99	
taggtctcaa tactcggtg ta	22
<210> 100	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 100	
tacaagtgga taccccaga	19
<210> 101	
<211> 19	
<212> DNA	
<213> H. sapiens	
<400> 101	
tataagtgga taccccaga	19
<210> 102	
<211> 26	
<212> DNA	
<213> H. sapiens	
<400> 102	
gggagaaaga atacattata attttt	26
<210> 103	
<211> 25	
<212> DNA	
<213> H. sapiens	
<400> 103	
gggagaaaga atacttataa ttttt	25
<210> 104	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 104	
ttccattggt tgccgatcaa c	21
<210> 105	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 105	
ttccattggt tgctgatcaa c	21
<210> 106	
<211> 21	
<212> DNA	
<213> H. sapiens	
<400> 106	
gaatgcattg aagagagtaa t	21

```

<210> 107
<211> 21
<212> DNA
<213> H. sapiens

<400> 107
gaatgcattg cagagagtaa t                21

<210> 108
<211> 22
<212> DNA
<213> H. sapiens

<400> 108
ctggtctgtg tggcaactgt ga                22

<210> 109
<211> 22
<212> DNA
<213> H. sapiens

<400> 109
ctggtctgtg tggcgactgt ga                22

<210> 110
<211> 19
<212> DNA
<213> H. sapiens

<400> 110
taagataaag ccttatgag                    19

<210> 111
<211> 19
<212> DNA
<213> H. sapiens

<400> 111
taagataaag acttatgag                    19

<210> 112
<211> 1976
<212> DNA
<213> H. sapiens

<220>
<221> CDS
<222> (11)...(1598)

<400> 112
taagaccagg atg tct ctg aaa tgg acg tca gtc ttt ctg ctg ata cag    49
      Met Ser Leu Lys Trp Thr Ser Val Phe Leu Leu Ile Gln
        1              5              10

ctc agt tgt tac ttt agc tct gga agc tgt gga aag gtg cta gtg tgg    97
Leu Ser Cys Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp
  15              20              25

ccc aca gaa tac agc cat tgg ata aat atg aag aca atc ctg gaa gag    145
Pro Thr Glu Tyr Ser His Trp Ile Asn Met Lys Thr Ile Leu Glu Glu
  30              35              40              45

```



ctt gtt cag agg ggt cat gag gtg act gtg ttg aca tct tcg gct tct Leu Val Gln Arg Gly His Glu Val Thr Val Leu Thr Ser Ser Ala Ser	193
50 55 60	
act ctt gtc aat gcc agt aaa tca tct gct att aaa tta gaa gtt tat Thr Leu Val Asn Ala Ser Lys Ser Ser Ala Ile Lys Leu Glu Val Tyr	241
65 70 75	
cct aca tct tta act aaa aat gat ttg gaa gat tct ctt ctg aaa att Pro Thr Ser Leu Thr Lys Asn Asp Leu Glu Asp Ser Leu Leu Lys Ile	289
80 85 90	
ctc gat aga tgg ata tat ggt gtt tca aaa aat aca ttt tgg tca tat Leu Asp Arg Trp Ile Tyr Gly Val Ser Lys Asn Thr Phe Trp Ser Tyr	337
95 100 105	
ttt tca caa tta caa gaa ttg tgt tgg gaa tat tat gac tac agt aac Phe Ser Gln Leu Gln Glu Leu Cys Trp Glu Tyr Tyr Asp Tyr Ser Asn	385
110 115 120 125	
aag ctc tgt aaa gat gca gtt ttg aat aag aaa ctt atg atg aaa cta Lys Leu Cys Lys Asp Ala Val Leu Asn Lys Lys Leu Met Met Lys Leu	433
130 135 140	
caa gag tca aag ttt gat gtc att ctg gca gat gcc ctt aat ccc tgt Gln Glu Ser Lys Phe Asp Val Ile Leu Ala Asp Ala Leu Asn Pro Cys	481
145 150 155	
ggg gag cta ctg gct gaa cta ttt aac ata ccc ttt ctg tac agt ctt Gly Glu Leu Leu Ala Glu Leu Phe Asn Ile Pro Phe Leu Tyr Ser Leu	529
160 165 170	
cga ttc tct gtt ggc tac aca ttt gag aag aat ggt gga gga ttt ctg Arg Phe Ser Val Gly Tyr Thr Phe Glu Lys Asn Gly Gly Gly Phe Leu	577
175 180 185	
ttc cct cct tcc tat gta cct gtt gtt atg tca gaa tta agt gat caa Phe Pro Pro Ser Tyr Val Pro Val Val Met Ser Glu Leu Ser Asp Gln	625
190 195 200 205	
atg att ttc atg gag agg ata aaa aat atg ata cat atg ctt tat ttt Met Ile Phe Met Glu Arg Ile Lys Asn Met Ile His Met Leu Tyr Phe	673
210 215 220	
gac ttt tgg ttt caa att tat gat ctg aag aag tgg gac cag ttt tat Asp Phe Trp Phe Gln Ile Tyr Asp Leu Lys Lys Trp Asp Gln Phe Tyr	721
225 230 235	
agt gaa gtt cta gga aga ccc act aca tta ttt gag aca atg ggg aaa Ser Glu Val Leu Gly Arg Pro Thr Thr Leu Phe Glu Thr Met Gly Lys	769
240 245 250	
gct gaa atg tgg ctc att cga acc tat tgg gat ttt gaa ttt cct cgc Ala Glu Met Trp Leu Ile Arg Thr Tyr Trp Asp Phe Glu Phe Pro Arg	817
255 260 265	
cca ttc tta cca aat gtt gat ttt gtt gga gga ctt cac tgt aaa cca Pro Phe Leu Pro Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro	865
270 275 280 285	
gcc aaa ccc ctg cct aag gaa atg gaa gag ttt gtg cag agc tct gga	913

Ala	Lys	Pro	Leu	Pro	Lys	Glu	Met	Glu	Glu	Phe	Val	Gln	Ser	Ser	Gly	
				290					295						300	
gaa	aat	ggt	att	gtg	gtg	ttt	tct	ctg	ggg	tcg	atg	atc	agt	aac	atg	961
Glu	Asn	Gly	Ile	Val	Val	Phe	Ser	Leu	Gly	Ser	Met	Ile	Ser	Asn	Met	
			305					310					315			
tca	gaa	gaa	agt	gcc	aac	atg	att	gca	tca	gcc	ctt	gcc	cag	atc	cca	1009
Ser	Glu	Glu	Ser	Ala	Asn	Met	Ile	Ala	Ser	Ala	Leu	Ala	Gln	Ile	Pro	
			320				325					330				
caa	aag	gtt	cta	tgg	aga	ttt	gat	ggc	aag	aag	cca	aat	act	tta	ggt	1057
Gln	Lys	Val	Leu	Trp	Arg	Phe	Asp	Gly	Lys	Lys	Pro	Asn	Thr	Leu	Gly	
	335					340					345					
tcc	aat	act	cga	ctg	tac	aag	tgg	tta	ccc	cag	aat	gac	ctt	ctt	ggt	1105
Ser	Asn	Thr	Arg	Leu	Tyr	Lys	Trp	Leu	Pro	Gln	Asn	Asp	Leu	Leu	Gly	
	350				355					360					365	
cat	ccc	aaa	acc	aaa	gct	ttt	ata	act	cat	ggt	gga	acc	aat	ggc	atc	1153
His	Pro	Lys	Thr	Lys	Ala	Phe	Ile	Thr	His	Gly	Gly	Thr	Asn	Gly	Ile	
				370					375					380		
tat	gag	gcg	atc	tac	cat	ggg	atc	cct	atg	gtg	ggc	att	ccc	ttg	ttt	1201
Tyr	Glu	Ala	Ile	Tyr	His	Gly	Ile	Pro	Met	Val	Gly	Ile	Pro	Leu	Phe	
			385					390					395			
gcg	gat	caa	cat	gat	aac	att	gct	cac	atg	aaa	gcc	aag	gga	gca	gcc	1249
Ala	Asp	Gln	His	Asp	Asn	Ile	Ala	His	Met	Lys	Ala	Lys	Gly	Ala	Ala	
		400				405						410				
ctc	agt	gtg	gac	atc	agg	acc	atg	tca	agt	aga	gat	ttg	ctc	aat	gca	1297
Leu	Ser	Val	Asp	Ile	Arg	Thr	Met	Ser	Ser	Arg	Asp	Leu	Leu	Asn	Ala	
	415					420					425					
ttg	aag	tca	gtc	att	aat	gac	cct	gtc	tat	aaa	gag	aat	gtc	atg	aaa	1345
Leu	Lys	Ser	Val	Ile	Asn	Asp	Pro	Val	Tyr	Lys	Glu	Asn	Val	Met	Lys	
	430				435					440					445	
tta	tca	aga	att	cat	cat	gac	caa	cca	atg	aag	ccc	ctg	gat	cga	gca	1393
Leu	Ser	Arg	Ile	His	His	Asp	Gln	Pro	Met	Lys	Pro	Leu	Asp	Arg	Ala	
				450					455					460		
gtc	ttc	tgg	att	gag	ttt	gtc	atg	cgc	cac	aaa	gga	gcc	aag	cac	ctt	1441
Val	Phe	Trp	Ile	Glu	Phe	Val	Met	Arg	His	Lys	Gly	Ala	Lys	His	Leu	
			465					470					475			
cga	gtc	gca	gct	cac	aac	ctc	acc	tgg	atc	cag	tac	cac	tct	ttg	gat	1489
Arg	Val	Ala	Ala	His	Asn	Leu	Thr	Trp	Ile	Gln	Tyr	His	Ser	Leu	Asp	
		480					485					490				
gtg	ata	gca	ttc	ctg	ctg	gcc	tgc	gtg	gca	act	gtg	ata	ttt	atc	atc	1537
Val	Ile	Ala	Phe	Leu	Leu	Ala	Cys	Val	Ala	Thr	Val	Ile	Phe	Ile	Ile	
	495					500					505					
aca	aaa	ttt	tgc	ctg	ttt	tgt	ttc	cga	aag	ctt	gcc	aaa	aca	gga	aag	1585
Thr	Lys	Phe	Cys	Leu	Phe	Cys	Phe	Arg	Lys	Leu	Ala	Lys	Thr	Gly	Lys	
	510				515					520					525	
aag	aag	aaa	aga	g	attagttata	tcaaaagcct	gaagtggaat	gactgaaaga								1638
Lys	Lys	Lys	Arg													

```

tgggactcct cctttatttc agcatggagg gttttaaatg gaggatttcc tttttcctgt 1698
gacaaaacat cttttcacta cttacctgt taagacaaaa tttattttcc agggatttaa 1758
tacgtacttt agttggaatt attctatgtc aatgattttt aagctatgaa aaatacaatg 1818
gggggaagga tagcatttgg agatatacct aatgttaaata gacgagttac tggatgcagc 1878
acgccaacat ggcacatgta tacatatgta gctaacctca cgttgtgcac atgtacccta 1938
aaacttaaaag tataatttaa aaaaagcaaa ggggtaccg 1976

```

&lt;210&gt; 113

&lt;211&gt; 530

&lt;212&gt; PRT

&lt;213&gt; H. sapiens

&lt;400&gt; 113

```

Met Ser Leu Lys Trp Thr Ser Val Phe Leu Leu Ile Gln Leu Ser Cys
1      5      10      15
Tyr Phe Ser Ser Gly Ser Cys Gly Lys Val Leu Val Trp Pro Thr Glu
20      25      30
Tyr Ser His Trp Ile Asn Met Lys Thr Ile Leu Glu Leu Val Gln
35      40      45
Arg Gly His Glu Val Thr Val Leu Thr Ser Ser Ala Ser Thr Leu Val
50      55      60
Asn Ala Ser Lys Ser Ser Ala Ile Lys Leu Glu Val Tyr Pro Thr Ser
65      70      75      80
Leu Thr Lys Asn Asp Leu Glu Asp Ser Leu Leu Lys Ile Leu Asp Arg
85      90      95
Trp Ile Tyr Gly Val Ser Lys Asn Thr Phe Trp Ser Tyr Phe Ser Gln
100     105     110
Leu Gln Glu Leu Cys Trp Glu Tyr Tyr Asp Tyr Ser Asn Lys Leu Cys
115     120     125
Lys Asp Ala Val Leu Asn Lys Lys Leu Met Met Lys Leu Gln Glu Ser
130     135     140
Lys Phe Asp Val Ile Leu Ala Asp Ala Leu Asn Pro Cys Gly Glu Leu
145     150     155     160
Leu Ala Glu Leu Phe Asn Ile Pro Phe Leu Tyr Ser Leu Arg Phe Ser
165     170     175
Val Gly Tyr Thr Phe Glu Lys Asn Gly Gly Gly Phe Leu Phe Pro Pro
180     185     190
Ser Tyr Val Pro Val Val Met Ser Glu Leu Ser Asp Gln Met Ile Phe
195     200     205
Met Glu Arg Ile Lys Asn Met Ile His Met Leu Tyr Phe Asp Phe Trp
210     215     220
Phe Gln Ile Tyr Asp Leu Lys Lys Trp Asp Gln Phe Tyr Ser Glu Val
225     230     235     240
Leu Gly Arg Pro Thr Thr Leu Phe Glu Thr Met Gly Lys Ala Glu Met
245     250     255
Trp Leu Ile Arg Thr Tyr Trp Asp Phe Glu Phe Pro Arg Pro Phe Leu
260     265     270
Pro Asn Val Asp Phe Val Gly Gly Leu His Cys Lys Pro Ala Lys Pro
275     280     285
Leu Pro Lys Glu Met Glu Glu Phe Val Gln Ser Ser Gly Glu Asn Gly
290     295     300
Ile Val Val Phe Ser Leu Gly Ser Met Ile Ser Asn Met Ser Glu Glu
305     310     315     320
Ser Ala Asn Met Ile Ala Ser Ala Leu Ala Gln Ile Pro Gln Lys Val
325     330     335
Leu Trp Arg Phe Asp Gly Lys Lys Pro Asn Thr Leu Gly Ser Asn Thr
340     345     350
Arg Leu Tyr Lys Trp Leu Pro Gln Asn Asp Leu Leu Gly His Pro Lys
355     360     365
Thr Lys Ala Phe Ile Thr His Gly Gly Thr Asn Gly Ile Tyr Glu Ala
370     375     380

```

Ile Tyr His Gly Ile Pro Met Val Gly Ile Pro Leu Phe Ala Asp Gln  
 385 390 395 400  
 His Asp Asn Ile Ala His Met Lys Ala Lys Gly Ala Ala Leu Ser Val  
 405 410 415  
 Asp Ile Arg Thr Met Ser Ser Arg Asp Leu Leu Asn Ala Leu Lys Ser  
 420 425 430  
 Val Ile Asn Asp Pro Val Tyr Lys Glu Asn Val Met Lys Leu Ser Arg  
 435 440 445  
 Ile His His Asp Gln Pro Met Lys Pro Leu Asp Arg Ala Val Phe Trp  
 450 455 460  
 Ile Glu Phe Val Met Arg His Lys Gly Ala Lys His Leu Arg Val Ala  
 465 470 475 480  
 Ala His Asn Leu Thr Trp Ile Gln Tyr His Ser Leu Asp Val Ile Ala  
 485 490 495  
 Phe Leu Leu Ala Cys Val Ala Thr Val Ile Phe Ile Ile Thr Lys Phe  
 500 505 510  
 Cys Leu Phe Cys Phe Arg Lys Leu Ala Lys Thr Gly Lys Lys Lys  
 515 520 525  
 Arg Asp  
 530

<210> 114  
 <211> 2312  
 <212> DNA  
 <213> H. sapiens  
 <220>  
 <221> exon  
 <222> (692)...(1425)

<400> 114  
 accctcctgc tcccatctgc catgatcact ggaaaaccct catttatattt ttaaagggtc 60  
 cagaaaatgc taatctatag agatagaaat tagattagt gttgcctagg gtaggatgga 120  
 tgcaaaattt cagagtgggg ggtagaggc tattgtatag aatcttttgg agataaatact 180  
 gattattgta gtgaaagtaa aattctgtga atatactagg aaacattgaa ctgtacacac 240  
 taattgggtga gtcatatggt atatgaatta tgtgtcaaca aagttttaga agacattact 300  
 tgcaccacga tattaataaaa tgccgtttga ctgtgtataat tacttcttct ctctatgtca 360  
 agggcaccga acaggcagga gcctctcact tgccactgtt cttacacagta ttataaaata 420  
 attacataag acagggttact tacatattct aggtcataaa aattattgct tgactagagt 480  
 aattgtaaac ataaaagaac accaaacaca ctaaaataaa tatgaggta tcaatctttt 540  
 gttgggtctcc ttggcatgca cctattcaga ctgttagtat tatgtattta cttcaaattt 600  
 tagcagttat attttaactt gattgatttt tcctcagata taagtatgag aatgacaga 660  
 aagaaacaac aactggaaaa gaagcattgc ataagaccag gatgtctctg aaatggacgt 720  
 cagtctttct gctgatacag ctccagttgtt acttttagctc tggaagctgt ggaaagggtc 780  
 tagtgtggcc cacagaatac agccattgga taaatatgaa gacaatcctg gaagagcttg 840  
 ttccagagggg tcatgaggtg actgtgttga catcttcggc ttctactctt gtcaatgcc 900  
 gtaaatcatc tgctattaaa ttagaagttt atcctacatc tttaactaaa aatgattttg 960  
 aagattctct tctgaaaatt ctcgatagat ggatatatgg tgtttcaaaa aatacatttt 1020  
 ggtcatattt ttcacaatta caagaattgt gttgggaata ttatgactac agtaacaagc 1080  
 tctgtaaaga tgcagttttg aataagaaac ttatgatgaa actacaagag tcaaagtttg 1140  
 atgtcattct ggcagatgcc cttaatccct gtggtgagct actggctgaa ctatttaaca 1200  
 taccctttct gtacagtctt cgattctctg ttggctacac atttgagaag aatgggtggag 1260  
 gatttctgtt ccctccttcc tatgtacctg ttgttatgtc agaattaagt gatcaaatga 1320  
 ttttcatgga gaggataaaa aatatgatac atatgcttta ttttgacttt tggtttcaaa 1380  
 tttatgatct gaagaagtgg gaccagtttt atagtgaagt tctaggttaag tcatgtgtct 1440  
 aactgggtgct tattaaagttc taacttttct gtgcctttga aggtgagctt atataaatat 1500  
 aatgtcagaa gatagtgttt ttaagggaaa ttatgaattg caaatgtaag atgatctatc 1560  
 agtctcaaaa atattataga atgttgacct tatagaatca gttagaaccc tggggccatc 1620  
 actactacag gacaccacga gagtcataaa ccttcattgt aaagcactaa tgatttcttt 1680  
 aaactatcac atatcatttt gctatacatt ttttcatctt taaaaaaagt caatagatac 1740  
 ctcaagaac atcttcatga aggcagacat ataaatttag tatttacaca tatttctaga 1800  
 aaaattatca atgcaggatt gaggaatttg tttctctttg agttcctcag tttcctcatt 1860

tagaaattaa	atattgtttt	tcatgtaaga	aggatttcctt	cacagttgag	taatatagtg	1920
gctctactcc	agaaacagaa	gcctaaaact	tgagatttct	aatgtttata	cattccttca	1980
ataacagggt	gacaattatt	tctttcaaaa	actgaaatct	tggtgaaagt	gaacatctaa	2040
gttttaattct	atatttttatt	aaactgcatc	tctccatcaa	agaaaatagg	ggccaaatta	2100
agggagagca	catatctcta	tgtcaataaa	ttctgaaaat	gttttaattc	tcatttgtaa	2160
atatattttat	tttaaaaatc	taattatatt	aagatctttac	gatgaaccaa	gacagtagta	2220
ggtgtaaaga	tttcagtgtt	gagctcaaaa	aactcatggg	ttactttgag	aaccaaggat	2280
caagggtctag	cttaataaac	tgtagacact	ag			2312

<210> 115  
 <211> 1021  
 <212> DNA  
 <213> H. sapiens

<220>  
 <221> exon  
 <222> (413)...(565)

<400> 115						
accatgatcc	aatcacctgc	cactgggtcc	ctccctggac	acatggggat	tatggggatt	60
ataattcaag	atgagaggag	atattgggtg	ggacagtcaa	accatattag	tgacttattt	120
taataattat	ttatgattgt	gaatatactg	atgtttacatt	aaagatgtga	tttcttctta	180
cagatctctg	aatacattgc	cttccttata	tatacatatg	agcaacatat	gcaataaata	240
aaatctaaat	tatgactata	tataaatgta	tttatatata	ttttatcaat	gcacagacat	300
tttatatatg	tttgggtatg	ttattccaag	tcctttcagg	aaaataacctg	catattcaaa	360
taacaattct	cgtgttagct	accttttgtt	ttgttttgtt	tttttccatc	aggaagacct	420
actacattat	ttgagacaat	ggggaaagct	gaaatgtggc	tcattcgaac	ctattgggat	480
tttgaatttc	ctcgccatt	cttaccaaa	gttgattttg	ttggaggact	tcactgtaaa	540
ccagccaaac	ccctgcctaa	ggtaaatgta	ttctgttttc	attgttttgc	ttgacatttt	600
cagaaggaa	ggctggatat	gtttctttca	gagtgtttta	ctcagagtga	ggggaatatg	660
ggaggtcaaa	aacaaggact	tgccattaga	aaatcatata	tttctgtagt	atcacaagta	720
tgtgaatgtt	attatcatta	aagaccaaa	aggtttacta	gggagatttt	gaaaacagg	780
ttgggttaa	taaggccttc	attgtgccac	ccaaaagata	gtatgattca	tttcttcaaa	840
aaatatttgt	agagtgatta	atacaacca	caggtaagt	ctggattttc	agagaataaa	900
ggtagcacag	tttctgctcc	ctcatgcctt	acattgtact	ttgaaagata	gaataaaaac	960
aagtgaaaaa	gaaaagtcta	aaaagtgtta	ttaaggaaag	accacaatga	taaagaaata	1020
t						1021

<210> 116  
 <211> 480  
 <212> DNA  
 <213> H. sapiens

<220>  
 <221> exon  
 <222> (43)...(174)

<400> 116						
tgctgttgct	cttttctgat	agaacaaatt	ctttcttcac	aggaaatgga	agagtttgtg	60
cagagctctg	gagaaaatgg	tattgtgggt	ttttctctgg	ggtcgatgat	cagtaacatg	120
tcagaagaaa	gtgccaacat	gattgcatca	gcccttgccc	agatcccaca	aaaggttaga	180
taaagtgcct	taactgtgga	tggtacttaa	atgaatctgt	taaactcttc	aagagtcocat	240
tacagaaaatg	ttctgcctga	aaatttaact	gctatgatag	ttctaattat	ctcagacatc	300
tgttcaaagc	aaaaacatat	atggaagatc	ttaaaatcat	aaagagagga	gttttggttg	360
ataataacgt	tggcattaat	attgtgatca	gaaggaaata	tatttaagag	gtgctagtga	420
agtttggtat	tatcatggta	tcgtagcatg	tacatagaaa	tcactaaatt	ctgccctgtc	480

<210> 117  
 <211> 1602  
 <212> DNA  
 <213> H. sapiens

<220>  
 <221> exon  
 <222> (368) ... (455)  
  
 <221> exon  
 <222> (1295) ... (1514)

<400> 117  
 tgagtcgaagg gctgactttg aatagaatgg gaggtagggt tggcctaagc agcttaactt 60  
 ttcccttttag catagagttt ggggttgccaa gatttatatt cctttcacaa tctcatgtgt 120  
 cttagctatta tgtagaaat gtcattattt ctttatatac aaaattgatt ataaaagtaa 180  
 cgacattaaa cgtgggtatt caacttacct caaactttta gtagttctca ttacttgaca 240  
 tcaacttctt ttatttcttc atcttttata tggattaact aactgattat taatctcttc 300  
 agaattctaa catgctatgt ttttagagtt ctattcattg aacaagatat tttccttgcc 360  
 ctaacaggtt ctatggagat ttgatggcaa gaagccaaat actttagggt ccaatactcg 420  
 actgtacaag tggttacccc agaattgacct tcttggttaag attctggaga acaaacagtg 480  
 aatatattag taacagcaaa ttggagtgat aatagttcaa cataaaacaa acatatttag 540  
 catttattat tggaaaacta aaaaacaaat caaatttaac tactttatat ttattttcca 600  
 gtcttagtat aaaaagaatg cactatagta gttggcattt tattacatac agtcacattc 660  
 tttatgggtc gaataaaaat ctctttgttc aggtgtaatt tcctctcaca ggttttaaat 720  
 aacatcctgg attttctgtc tgtctcctat ttatgcagct ttacctctgt tctttccctt 780  
 actgcagggt tatttcaaca ggcactgaaa aatagcggac acttttctat taccagtgc 840  
 tctacttttt atgggaataa ataaccaatc tttatcatga taaaatgata acacatttca 900  
 tgatgatgca taaccggtcc ttcctcagcc ccacctccac cctactccct gctgcctttt 960  
 aaaaaaaatt aaatatttta aatattttta gtatttaaat attttttaaa tatgtaaagt 1020  
 tgacctcatt atttataata cttaaaagac caggttcttg tatacccaat cttattcttt 1080  
 ttttttgcac attttaattt ttttaattag aatatgcttt ttcattttgt tcacctggca 1140  
 attcttctga aatttgaaaa caatttcaat gcagttttgt ggggtataatg ttacctaggg 1200  
 aacagttttg ctttaagttc cttatattgt gcatttctta ttcaattctc ataccttgta 1260  
 attaataatt ttgttaaaat gcatccactt ttaggtcatc ccaaaaccaa agcttttata 1320  
 actcctgtg gaaccaatgg catctatgag gcgactacc atgggatccc tatgggtggg 1380  
 attcccttgt ttgcggtatc acatgataac attgtcaca tgaaagccaa gggagcagcc 1440  
 ctcagtgtgg acatcaggac catgtcaagt agagatttgc tcaatgcatt gaagtcagtc 1500  
 attaatgacc ctgtgtgagt attacagttt tgtgaccagg tggattttat aaattatttt 1560  
 gtcaacagtg aatatgaatt ttaaccggtt ttaagagac ta 1602

<210> 118  
 <211> 978  
 <212> DNA  
 <213> H. sapiens

<220>  
 <221> exon  
 <222> (326) ... (978)

<400> 118  
 caaaaagatc atttctcaaat tccattttcca ctatcttact tatagcactt agaattggctc 60  
 ataataatttt ctgctccaga aaacattaac tttcccacccg aaaattccat ttttcatttt 120  
 taaagggtatt tgtcagtgat aaaactccaa tttaaaaacc aaactttctg taatgacatg 180  
 aattaaaaca ttgaaatttc atgccaattc agtgacactt actttcaatc atttgtgtga 240  
 cactttttcaa agaccatcca tagacttgat atgcttaagc aataaattta cttttaatgt 300  
 tgatatcttt atatttatcc ttcagctata aagagaatgt catgaaatta tcaagaattc 360  
 atcatgacca accaatgaag cccctggatc gagcagttt ctggattgag tttgtcatgc 420  
 gccacaaagg agccaagcac cttcgagtgc cagctcacaa cctcacctgg atccagtacc 480  
 actcttttga tgtgatagca ttctgtctgg cctgcgtggc aactgtgata tttatcatca 540  
 caaaaattttg cctgtttttgt ttccgaaaagc ttgcccacaa aggaaagaag aagaaaagag 600  
 attagttata tcaaaagcct gaagtggaaat gactgaaaga tgggactcct cttttatttc 660  
 agcatggagg gttttaaatg gaggatttcc tttttcctgt gacaaaacat cttttcacta 720  
 cttaccttgt taagacaaaa tttattttcc agggatttaa tacgtacttt agttggaatt 780  
 attctatgtc aatgattttt aagctatgaa aaatacaatg gggggaagga tagcatttgg 840  
 agatataacct aatgttaaat gacgagttac tggatgcagc acgccaacat ggcacatgta 900  
 tacatatgta gctaacctca cgttgtgcac atgtacccta aaacttaag tataatttaa 960

aaaaagcaaa gggtagcg 978

<210> 119  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 119  
catgcaccta ttcagactgt 20

<210> 120  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 120  
tgggtgtcct gtagtagtga 20

<210> 121  
<211> 25  
<212> DNA  
<213> H. sapiens

<400> 121  
attgattttt cctcagatat aagta 25

<210> 122  
<211> 22  
<212> DNA  
<213> H. sapiens

<400> 122  
tcataatttc ccttaaaaac ac 22

<210> 123  
<211> 22  
<212> DNA  
<213> H. sapiens

<400> 123  
atatgtttgg gtatgttatt cc 22

<210> 124  
<211> 18  
<212> DNA  
<213> H. sapiens

<400> 124  
ccatattccc ctcactct 18

<210> 125  
<211> 23  
<212> DNA  
<213> H. sapiens

<400> 125  
atacctgcat attcaaataa caa 23

<210> 126  
<211> 18  
<212> DNA  
<213> H. sapiens

<400> 126  
tatccagcca ttccttct 18  
<210> 127  
<211> 22  
<212> DNA  
<213> H. sapiens

<400> 127  
agttttgtgg gtataatgtt ac 22  
<210> 128  
<211> 19  
<212> DNA  
<213> H. sapiens

<400> 128  
aaacgggtta aaattcata 19  
<210> 129  
<211> 25  
<212> DNA  
<213> H. sapiens

<400> 129  
tcataccttg taattaataa ttttg 25  
<210> 130  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 130  
cgggttaaaa ttcatttca 20  
<210> 131  
<211> 18  
<212> DNA  
<213> H. sapiens

<400> 131  
tcatgccaat tcagtac 18  
<210> 132  
<211> 17  
<212> DNA  
<213> H. sapiens

<400> 132  
accctccatg ctgaaat 17  
<210> 133  
<211> 21  
<212> DNA  
<213> H. sapiens

<400> 133  
tcaaagacca tccatagact t 21  
<210> 134  
<211> 19



<212> DNA  
 <213> H. sapiens  
  
 <400> 134  
 ggagtcccat ctttcagtc 19  
  
 <210> 135  
 <211> 25  
 <212> DNA  
 <213> H. sapiens  
  
 <400> 135  
 attgattttt cctcagatat aagta 25  
  
 <210> 136  
 <211> 19  
 <212> DNA  
 <213> H. sapiens  
  
 <400> 136  
 atttactggc attgacaag 19  
  
 <210> 137  
 <211> 25  
 <212> DNA  
 <213> H. sapiens  
  
 <400> 137  
 attgattttt cctcagatat aagta 25  
  
 <210> 138  
 <211> 22  
 <212> DNA  
 <213> H. sapiens  
  
 <400> 138  
 tgtacagaaa gggatatgtta aa 22  
  
 <210> 139  
 <211> 20  
 <212> DNA  
 <213> H. sapiens  
  
 <400> 139  
 aaaaatkatt tggaagattc 20  
  
 <210> 140  
 <211> 22  
 <212> DNA  
 <213> H. sapiens  
  
 <400> 140  
 tcataatttc ccttaaaaac ac 22  
  
 <210> 141  
 <211> 23  
 <212> DNA  
 <213> H. sapiens  
  
 <400> 141  
 atacctgcat attcaaataa caa 23

<210> 142  
<211> 18  
<212> DNA  
<213> H. sapiens

<400> 142  
tatccagcca ttccttct 18

<210> 143  
<211> 25  
<212> DNA  
<213> H. sapiens

<400> 143  
tcataccttg taattaataa ttttg 25

<210> 144  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 144  
cgggttaaaa ttcatttca 20

<210> 145  
<211> 21  
<212> DNA  
<213> H. sapiens

<400> 145  
tcaaagacca tccatagact t 21

<210> 146  
<211> 19  
<212> DNA  
<213> H. sapiens

<400> 146  
ggagtcccat ctttcagtc 19

<210> 147  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 147  
tgatacagct cagttgttac 20

<210> 148  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 148  
tgatacagct cggttgttac 20

<210> 149  
<211> 20  
<212> DNA  
<213> H. sapiens

<400> 149

tggtgacatc ttcggcttct 20  
<210> 150  
<211> 20  
<212> DNA  
<213> H. sapiens  
<400> 150  
tggtgacatc gtcggcttct 20  
<210> 151  
<211> 23  
<212> DNA  
<213> H. sapiens  
<400> 151  
ctttaactaa aaatgatttg gaa 23  
<210> 152  
<211> 23  
<212> DNA  
<213> H. sapiens  
<400> 152  
ctttaactaa aaattatttg gaa 23  
<210> 153  
<211> 22  
<212> DNA  
<213> H. sapiens  
<400> 153  
tttaacatac cctttctgta ca 22  
<210> 154  
<211> 22  
<212> DNA  
<213> H. sapiens  
<400> 154  
tttaacatac cctttccgta ca 22  
<210> 155  
<211> 22  
<212> DNA  
<213> H. sapiens  
<400> 155  
ttggaggact tcactgtaaa cc 22  
<210> 156  
<211> 22  
<212> DNA  
<213> H. sapiens  
<400> 156  
ttggaggact tcagtgtaaa cc 22  
<210> 157  
<211> 23  
<212> DNA  
<213> H. sapiens

<400> 157  
tatgaggcga tctaccatgg gat 23  
<210> 158  
<211> 23  
<212> DNA  
<213> H. sapiens

<400> 158  
tatgaggcaa tctaccatgg gat 23  
<210> 159  
<211> 24  
<212> DNA  
<213> H. sapiens

<400> 159  
cccttgtttg cggatcaaca tgat 24  
<210> 160  
<211> 24  
<212> DNA  
<213> H. sapiens

<400> 160  
cccttgtttg tggatcaaca tgat 24  
<210> 161  
<211> 22  
<212> DNA  
<213> H. sapiens

<400> 161  
aaagagaatg tcatgaaatt at 22  
<210> 162  
<211> 22  
<212> DNA  
<213> H. sapiens

<400> 162  
aaagagaata tcatgaaatt at 22  
<210> 163  
<211> 21  
<212> DNA  
<213> H. sapiens

<400> 163  
gcttgccaaa acaggaaaga a 21  
<210> 164  
<211> 21  
<212> DNA  
<213> H. sapiens

<400> 164  
gcttgccaaa aaaggaaaga a 21

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/16675

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LEVESQUE E. ET AL.,: "Isolation and characterization of UGT2B15 : a UDP-Glucuronosyltransferase encoded by a polymorphic gene" PHARMACOGENETICS, vol. 7, no. 4, - August 1997 (1997-08) pages 317-325, XP000852552 cited in the application see whole doc. esp. results p.320 ff.</p> <p style="text-align: center;">--- -/--</p>	1-10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 November 1999

Date of mailing of the international search report

22/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

# INTERNATIONAL SEARCH REPORT

national Application No  
PCT/US 99/16675

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>RITTER J.K. ET AL.,: "Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells" J. BIOL. CHEMISTRY, vol. 265, no. 14, - 15 May 1990 (1990-05-15) pages 7900-7906, XP002121919 the whole document</p>	1-3
X	<p>JIN. C.J. ET AL.,: "cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily" BIOCHEM. BIOPHYS. RESEARCH COMMUNICATIONS, vol. 194, no. 1, - 15 July 1993 (1993-07-15) pages 496-503, XP002121839 cited in the application the whole document</p>	1-3
X	<p>WO 92 12987 A (US) 6 August 1992 (1992-08-06) see whole doc. esp. claims and summary</p>	1-10
A	<p>RITTER J.K. ET AL.,: "Cloning of two human liver bilirubin UDP-glucuronosyl-transferase cDNAs with expression in COS-1 cells" J. BIOL. CHEMISTRY, vol. 266, no. 2, - 15 January 1991 (1991-01-15) pages 1043-1047, XP002121838 the whole document</p>	1-3
A	<p>GREEN M D ET AL: "STABLE EXPRESSION OF A HUMAN LIVER UDP-GLUCURONOSYLTRANSFERASE (UGT2B15) WITH ACTIVITY TOWARD STEROID AND XENOBIOTIC SUBSTRATES" DRUG METABOLISM AND DISPOSITION, vol. 22, no. 5, 1 September 1994 (1994-09-01), pages 799-805, XP002039718 ISSN: 0090-9556 cited in the application</p>	
A	<p>CIOTTI ET AL: "GENETIC POLYMORPHISM IN THE HUMAN UGT1A6 (PLANAR PHENOL) UDP-GLUCURONOSYLTRANSFERASE: PHARMACOLOGICAL IMPLICATIONS" PHARMACOGENETICS, vol. 7, no. 7, 1997, pages 485-495 495, XP002113205 ISSN: 0960-314X the whole document</p>	
	-/--	

# INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 99/16675

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	DE WILDT S.N. ET AL.,: "Glucuronidation in humans" CLIN. PHARMACOKINETICS, vol. 36, no. 6, - June 1999 (1999-06) pages 439-452, XP002121840 the whole document ---	
P,X	LEVESQUE E. ET AL.,: "Characterization and substrate specificity of UGT2B4: a UDP-glucuronosyltransferase encoded by a polymorphic gene" PHARMACOGENETICS, vol. 9, no. 2, - April 1999 (1999-04) pages 207-216, XP000852554 the whole document ---	1-10
P,X	MACLEOD S.L. ET AL.,: "a genetic polymorphism in UGT2B15 as a risk factor for breast and prostate cancer" PROC. AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, - March 1999 (1999-03) pages 243-244, XP002121841 the whole document -----	1-10

## INTERNATIONAL SEARCH REPORT

### Information on patent family members

**national Application No**

PCT/US 99/16675

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9212987 A	06-08-1992	AU 1227892 A	27-08-1992



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**